[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 22621
1. Jiménez-Heffernan A, Gómez-Millán J, Sánchez De Mora E, Delgado Moreno J, Delgado Gil MM, Salgado C, Contreras Puertas P, Bermúdez Morales MC, López J, Paz Expósito J: [Quantitative salivary gland scintigraphy in head and neck cancer patients following radiotherapy]. Rev Esp Med Nucl; 2010 Jul-Aug;29(4):165-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To assess the role of quantitative salivary gland scintigraphy (SGS) in the detection of functional impairment of salivary glands in patients with head and neck cancer treated with radiotherapy (RT).
  • Three studies were performed to each patient: baseline, 3 and 18 months after RT.
  • Excretion fraction (EF), counts per minute/pixel/MBq (CMPM) and uptake percentage were obtained from time-activity curves from ROIs placed over parotid (PG) and submandibular glands (SMG) and related to the doses received by the PG.
  • CONCLUSIONS: EF was more sensitive than uptake in assessing post-RT impairment of salivary function.
  • In addition, it reflected functional recovery of parotid glands over time.

  • Genetic Alliance. consumer health - Salivary Gland Cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 Elsevier España, S.L. y SEMNIM. All rights reserved.
  • (PMID = 20462671.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


2. Sun JF, Zhao DD, Han XP, Jin HS, Yu L: [Dynamic detection of chimerism and fusion gene in chronic myeloid leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug;16(4):833-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study was aimed to investigate the chimerism and fusion gene expression in patients with CML after allo-HSCT, to analyse engraftment and minimal residual disease by using STR-PCR combined with RT-PCR qualitative and quantitative assays, and to evaluate their clinical value for predicting disease relapse.
  • Qualitative analysis of donor chimerism was performed by multiplex PCR amplification of STR markers and capillary electrophoresis with fluorescence detection, qualitative detection of bcr/abl transcripts was performed by RT-PCR.
  • The results showed that the 100% donor chimerism appeared in 4 patients on day 28 after transplantation and bcr/abl expression was negative, but the 4 patients were in status of unstable mixed chimerism (DC: 0% - 80.4%) at the different time points during the following up with bcr/abl gene positive.
  • It is concluded that the results of STR-PCR in the range of its sensitivity fully correspond with bcr/abl tests in patients.
  • The combination of STR-PCR with RT-PCR will provide a highly sensitive and valuable tool for evaluating engraftment, graft rejection, and relapse and predicting GVHD.


3. Nuyts S, Dirix P, Clement PM, Poorten VV, Delaere P, Schoenaers J, Hermans R, Van den Bogaert W: Impact of adding concomitant chemotherapy to hyperfractionated accelerated radiotherapy for advanced head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys; 2009 Mar 15;73(4):1088-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate the feasibility and efficacy of a hyperfractionated accelerated radiotherapy (RT) schedule combined with concomitant chemotherapy (Cx) in patients with locally advanced head-and-neck squamous cell carcinoma.
  • METHODS AND MATERIALS: Between 2004 and 2007, a total of 90 patients with locoregionally advanced head-and-neck squamous cell carcinoma underwent irradiation according to a hybrid fractionation schedule consisting of 20 fractions of 2 Gy (once daily) followed by 20 fractions of 1.6 Gy (twice daily) to a total dose of 72 Gy.
  • In comparison with the RT-only group, an improvement of 15% in both LRC (p = 0.03) and overall survival (p = 0.09) was observed.
  • No acute Grade 4 or 5 toxicity was seen, but incidences of Grade 3 acute mucositis (74.5% vs. 50.7%; p = 0.002) and dysphagia (82.2% vs. 47.9%; p < 0.001) were significantly higher in the chemoradiotherapy group compared with patients treated with RT alone.


Advertisement
4. Delaporte V, Muracciole X, Lechevallier E, Bastide C, Cowen D, Rossi D, Coulange C: [Prostate cancer at high risk of recurrence: results of 12 months of radiotherapy-hormone therapy]. Prog Urol; 2005 Apr;15(2):260-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Cancer de la prostate à haut risque de rechute. Résultats d'une RT-HT de 12 mois.
  • [MeSH-minor] Disease-Free Survival. Follow-Up Studies. Humans. Male. Neoplasm Recurrence, Local / epidemiology. Risk Factors

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15999604.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Androgen Antagonists; 33515-09-2 / Gonadotropin-Releasing Hormone
  •  go-up   go-down


5. Jeong WJ, Jung EJ, Hah JH, Kwon TK, Wu HG, Heo DS, Sung MW, Kim KH: Preliminary results of pre-radiation neck dissection in head and neck cancer patients undergoing organ preservation treatment. Acta Otolaryngol Suppl; 2007 Oct;(558):121-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: Pre-RT ND in patients with HNSCC undergoing organ preservation treatment is safe, advantageous, poses no additional morbidity owing to the elective neck dissection, and may possibly improve survival outcomes.
  • OBJECTIVE: Establish the role of pre-radiation neck dissection (pre-RT ND) in patients with head & neck squamous cell carcinoma (HNSCC) undergoing organ preservation treatment.
  • MATERIALS AND METHODS: Fourteen patients with histologically confirmed HNSCC in stages III approximately IV with proven regional metastasis were enrolled in the organ preservation approach incorporating pre-RT ND at a tertiary referral center between May 1998 and August 2004.
  • RESULTS: Disease free survival was significantly better for the pre-RT ND group.
  • There was no significant difference in overall survival, pattern of recurrence, and primary organ preservation rate between the two groups.
  • No significant morbidity owing to neck dissection was noted in patients who underwent neck dissection.
  • Although the delivery of radiation to the primary site was delayed for patients in the pre-RT ND group, it did not influence the major outcomes.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bridged Compounds / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local / epidemiology. Radiotherapy Dosage. Taxoids / administration & dosage

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17882582.001).
  • [ISSN] 0365-5237
  • [Journal-full-title] Acta oto-laryngologica. Supplementum
  • [ISO-abbreviation] Acta Otolaryngol Suppl
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Bridged Compounds; 0 / Taxoids; 1605-68-1 / taxane; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


6. Tan IL, Dimamay MP, Buerano CC, Alfon JA, Tanig CZ, Matias RR, Natividad FF: Development and evaluation of a fluorogenic real-time RT-PCR for the detection of dengue 3 virus. J Med Virol; 2010 Dec;82(12):2053-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development and evaluation of a fluorogenic real-time RT-PCR for the detection of dengue 3 virus.
  • A dengue-3-specific real-time reverse transcriptase-polymerase chain reaction (RT-PCR) was developed using the novel Light Upon eXtension (LUX™) fluorogenic technology.
  • Moreover, the fluorogenic assay was evaluated by using clinical specimens and comparing test results with historical data obtained from conventional RT-PCR, which served as the criterion standard.
  • Using patient sera as test samples, the assay demonstrated 95.45% sensitivity and 100% specificity, respectively.
  • These results reveal that the real-time RT-PCR assay may be utilized as a rapid, convenient, and sensitive tool for the detection of dengue 3 in clinical and laboratory specimens.

  • MedlinePlus Health Information. consumer health - Dengue.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20981793.001).
  • [ISSN] 1096-9071
  • [Journal-full-title] Journal of medical virology
  • [ISO-abbreviation] J. Med. Virol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fluorescent Dyes; 0 / NS1 protein, Dengue virus type 3; 0 / Oligonucleotide Probes; 0 / RNA, Viral; 0 / Viral Nonstructural Proteins
  •  go-up   go-down


7. Su AW, Jani AB: Chronic genitourinary and gastrointestinal toxicity of prostate cancer patients undergoing pelvic radiotherapy with intensity-modulated versus 4-field technique. Am J Clin Oncol; 2007 Jun;30(3):215-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The records of consecutive prostate cancer patients receiving RT at a single institution with a minimum follow-up of 120 days were reviewed; 48 of these patients received a prostate boost preceded by pelvic radiotherapy (PRT), 14 with IMRT (IM-PRT), and 34 with 4-field (4F-PRT).
  • Dosimetric endpoints for the bladder, rectum, composite, and target for the PRT plans were compared using the 2-tailed t test.
  • Late RTOG GU and GI toxicity were compared using the chi test.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Clin Oncol. 2007 Dec;30(6):666 [18091067.001]
  • (PMID = 17551295.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Wisnewski RG, Lauwereyns J: Systemic dizocilpine (MK-801) facilitates performance in opposition to response bias. Behav Brain Funct; 2007;3:48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The current study examined the effects of the noncompetitive N-methyl-D-aspartate (NMDA)-receptor antagonist dizocilpine (MK-801) on reaction time (RT) in a nose-poke task with rats completing an asymmetric reward schedule.
  • Reaction times (ms) were faster for large-reward trials than for small-reward trials, replicating previous findings.
  • At a dosage of MK-801 (0.04 mg/kg), there was no significant influence of on RT in large-reward trials.
  • In contrast, the same dosage of MK-801 in small-reward trials produced a decrease in RT as compared to the control condition, implying an improvement of performance.
  • Below 0.04 mg/kg of MK-801, a steady decrease of RT in small-trials was seen as a function of dosage.
  • Above 0.04 mg/kg of MK-801, the majority of rats failed to perform the task at all, whereas the rats that did manage to perform the criterion of 80 correct trials in a session showed no difference in RT between large- and small-reward trials.
  • These data indicate that the systemic administration of a relatively small dosage of MK-801 facilitates performance when reward is small.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci. 2000 Aug 15;20(16):6282-8 [10934279.001]
  • [Cites] Nature. 2002 Jul 25;418(6896):413-7 [12140557.001]
  • [Cites] J Neurosci. 2003 Jan 1;23(1):1-6 [12514193.001]
  • [Cites] Curr Opin Neurobiol. 2003 Dec;13(6):685-90 [14662369.001]
  • [Cites] J Exp Psychol Anim Behav Process. 2006 Oct;32(4):467-73 [17044749.001]
  • [Cites] Science. 2005 Jun 17;308(5729):1798-801 [15961671.001]
  • [Cites] Annu Rev Psychol. 2006;57:87-115 [16318590.001]
  • [Cites] Trends Cogn Sci. 2006 Feb;10(2):47-9 [16359911.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 17;101(33):12336-41 [15302926.001]
  • (PMID = 17880723.001).
  • [ISSN] 1744-9081
  • [Journal-full-title] Behavioral and brain functions : BBF
  • [ISO-abbreviation] Behav Brain Funct
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2075506
  •  go-up   go-down


9. Mattson CL, Campbell RT, Karabatsos G, Agot K, Ndinya-Achola JO, Moses S, Bailey RC: Scaling sexual behavior or "sexual risk propensity" among men at risk for HIV in Kisumu, Kenya. AIDS Behav; 2010 Feb;14(1):162-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We found no evidence of differential item function at different time points (except for reporting a concurrent partners when comparing 6 and 12 month follow-up visits) or with respect to the language with which the instrument was administered.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2007 Feb 24;369(9562):643-56 [17321310.001]
  • [Cites] Lancet. 2007 Feb 24;369(9562):657-66 [17321311.001]
  • [Cites] Sex Transm Dis. 2007 Oct;34(10):731-6 [17495591.001]
  • [Cites] Qual Life Res. 2008 Mar;17(2):275-90 [18246447.001]
  • [Cites] Sex Transm Dis. 2000 Mar;27(3):127-32 [10726643.001]
  • [Cites] AIDS. 2000 Oct 20;14(15):2361-70 [11089625.001]
  • [Cites] Int J STD AIDS. 2001 Jun;12(6):365-75 [11368817.001]
  • [Cites] J Pers Assess. 2001 Jun;76(3):379-95 [11499453.001]
  • [Cites] Lancet Infect Dis. 2001 Nov;1(4):223-31 [11871509.001]
  • [Cites] Psychol Addict Behav. 2002 Mar;16(1):64-7 [11934088.001]
  • [Cites] Am J Public Health. 2002 May;92(5):818-25 [11988453.001]
  • [Cites] Sex Transm Dis. 2002 Sep;29(9):530-2 [12218844.001]
  • [Cites] Ann Behav Med. 2003 Oct;26(2):76-103 [14534027.001]
  • [Cites] Ann Behav Med. 2003 Oct;26(2):104-23 [14534028.001]
  • [Cites] Qual Life Res. 2004 Mar;13(2):531-40 [15085925.001]
  • [Cites] AIDS. 1991 Feb;5(2):181-5 [2031690.001]
  • [Cites] Am J Public Health. 1993 Aug;83(8):1139-43 [8342723.001]
  • [Cites] J Pers Assess. 1994 Jun;62(3):385-97 [8027907.001]
  • [Cites] J Pers Assess. 1995 Dec;65(3):586-601 [8609589.001]
  • [Cites] Sex Transm Dis. 1997 Feb;24(2):102-8 [9111756.001]
  • [Cites] Am J Public Health. 1998 Apr;88(4):671-4 [9551017.001]
  • [Cites] Am J Prev Med. 1998 Aug;15(2):103-13 [9713665.001]
  • [Cites] Health Educ Res. 1999 Feb;14(1):25-38 [10537945.001]
  • [Cites] Ann Behav Med. 2005 Apr;29(2):86-95; discussion 96-9 [15823781.001]
  • [Cites] AIDS Behav. 2005 Jun;9(2):135-43 [15933833.001]
  • [Cites] Respirology. 2005 Nov;10(5):587-93 [16268911.001]
  • [Cites] PLoS Med. 2005 Nov;2(11):e298 [16231970.001]
  • [ErratumIn] AIDS Behav. 2010 Feb;14(1):173
  • (PMID = 18651213.001).
  • [ISSN] 1573-3254
  • [Journal-full-title] AIDS and behavior
  • [ISO-abbreviation] AIDS Behav
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / U01 AI050440; United States / NIAID NIH HHS / AI / U01 AI050440-08
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS83247; NLM/ PMC2999988
  •  go-up   go-down


10. Corey DM, Kim HW, Salazar R, Illescas R, Villena J, Gutierrez L, Sanchez J, Tabet SR: Brief report: effectiveness of combination antiretroviral therapy on survival and opportunistic infections in a developing world setting: an observational cohort study. J Acquir Immune Defic Syndr; 2007 Apr 1;44(4):451-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All 564 initially antiretroviral-naive HIV-infected persons (mean CD4 count of 91 cells/mm3) who received combination ART were followed over time.
  • Among persons who initiated therapy with CD4 counts <100 cells/mm3, the overall survival rate at 3 years was 95%.
  • Patients who received 2 reverse transcriptase (RT) inhibitors plus a protease inhibitor had slightly better survival rates and less opportunistic disease in the first year of therapy as compared with those receiving 2 RT inhibitors and a nonnucleoside reverse transcriptase inhibitor or 3 RT inhibitors.


11. Hoshi H, O'Brien J, Mills SL: A novel fluorescent tracer for visualizing coupled cells in neural circuits of living tissue. J Histochem Cytochem; 2006 Oct;54(10):1169-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Staining the coupled cells by this means opens the door to many vital techniques including paired-cell electrophysiology, RT-PCR, and morphological characterization of previously unknown coupled cells.
  • Tracers commonly used at the present time are not generally suitable for these purposes in many tissues, including neurons.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Comp Neurol. 2000 Jan 3;416(1):19-29 [10578100.001]
  • [Cites] J Comp Neurol. 2005 May 9;485(3):191-201 [15791644.001]
  • [Cites] J Neurosci. 2000 Nov 15;20(22):8629-36 [11069972.001]
  • [Cites] J Neurosci. 2001 Jan 1;21(1):230-9 [11150340.001]
  • [Cites] Science. 2001 Jun 22;292(5525):2295-9 [11423653.001]
  • [Cites] J Comp Neurol. 2001 Jul 30;436(3):336-50 [11438934.001]
  • [Cites] J Neurosci. 2002 Jan 15;22(2):413-27 [11784786.001]
  • [Cites] J Neurophysiol. 2002 Jun;87(6):3048-58 [12037207.001]
  • [Cites] J Neurosci. 2003 Jul 30;23(17):6768-77 [12890770.001]
  • [Cites] Cell Commun Adhes. 2003 Jul-Dec;10(4-6):425-30 [14681052.001]
  • [Cites] Neuron. 2004 Feb 19;41(4):495-511 [14980200.001]
  • [Cites] Eur J Neurosci. 2004 May;19(10):2633-40 [15147297.001]
  • [Cites] J Neurosci. 2004 Jun 16;24(24):5632-42 [15201336.001]
  • [Cites] Annu Rev Neurosci. 2004;27:393-418 [15217338.001]
  • [Cites] Vis Neurosci. 2004 Mar-Apr;21(2):145-55 [15259566.001]
  • [Cites] J Physiol. 2004 Aug 15;559(Pt 1):215-30 [15235091.001]
  • [Cites] Science. 1977 Jan 21;195(4275):294-6 [831276.001]
  • [Cites] Nature. 1980 May 8;285(5760):101-2 [6246436.001]
  • [Cites] J Comp Neurol. 1991 Feb 15;304(3):491-501 [1850763.001]
  • [Cites] Neurosci Lett. 1991 Apr 29;125(2):187-90 [1715532.001]
  • [Cites] J Comp Neurol. 1992 Jul 1;321(1):133-49 [1613135.001]
  • [Cites] Vis Neurosci. 1992 Sep-Oct;9(3-4):279-90 [1390387.001]
  • [Cites] Vis Neurosci. 1994 May-Jun;11(3):549-60 [7518689.001]
  • [Cites] Nature. 1995 Oct 26;377(6551):734-7 [7477263.001]
  • [Cites] J Comp Neurol. 1997 Jul 14;383(4):512-28 [9208996.001]
  • [Cites] Vis Neurosci. 1998 Jul-Aug;15(4):765-77 [9682877.001]
  • [Cites] J Neurophysiol. 1999 Feb;81(2):908-20 [10036288.001]
  • [Cites] Jpn J Physiol. 1958 Dec 20;8(4):305-18 [13620382.001]
  • [Cites] J Physiol. 1959 Mar 3;145(2):289-325 [13642302.001]
  • [Cites] J Gen Physiol. 1959 Sep;43:159-88 [13798948.001]
  • [Cites] J Neurosci. 2004 Nov 17;24(46):10553-67 [15548670.001]
  • [Cites] J Neurosci. 2005 Jan 19;25(3):566-76 [15659592.001]
  • [Cites] Vis Neurosci. 2004 Sep-Oct;21(5):791-805 [15683564.001]
  • [Cites] Vis Neurosci. 1999 Nov-Dec;16(6):1181-9 [10614597.001]
  • (PMID = 16864895.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] ENG
  • [Grant] United States / NEI NIH HHS / EY / EY-10608; United States / NEI NIH HHS / EY / EY-12857; United States / NEI NIH HHS / EY / EY012857-06A1; United States / NEI NIH HHS / EY / R01 EY010121; United States / NEI NIH HHS / EY / R01 EY012857; United States / NEI NIH HHS / EY / EY-10121; United States / NEI NIH HHS / EY / R01 EY012857-06A1; United States / NEI NIH HHS / EY / P30 EY010608
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzoxazoles; 0 / Connexins; 0 / Eye Proteins; 0 / Fluorescent Dyes; 0 / Po-Pro-1; 0 / connexin 35 protein, vertebrate
  • [Other-IDs] NLM/ NIHMS17898; NLM/ PMC1851887
  •  go-up   go-down


12. Bergero R, Lanfranco L, Ghignone S, Bonfante P: Enhanced activity of the GmarMT1 promoter from the mycorrhizal fungus Gigaspora margarita at limited carbon supply. Fungal Genet Biol; 2007 Sep;44(9):877-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We previously reported the identification and the characterization of a metallothionein gene (GmarMT1) from the arbuscular mycorrhizal fungus Gigaspora margarita.
  • Here, we have used real-time quantitative RT-PCR to show that GmarMT1 expression was turned off during the symbiotic fungal growth in the hexose-rich mycorrhizal apoplast, whereas transcripts were abundant during all other fungal growth stages, when products of lipid breakdown and the glyoxylate cycle feed carbohydrate-consuming pathways.
  • In support of a nutritional regulation of GmarMT1 expression, we show that transcriptional activity of GmarMT1 promoter in yeast was strongly induced by glucose starvation (up to 20 times the basal level).

  • MedlinePlus Health Information. consumer health - Molds.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CARBON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17482490.001).
  • [ISSN] 1087-1845
  • [Journal-full-title] Fungal genetics and biology : FG & B
  • [ISO-abbreviation] Fungal Genet. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 7440-44-0 / Carbon; 9038-94-2 / Metallothionein
  •  go-up   go-down


13. Barber M, Murrell A, Ito Y, Maia AT, Hyland S, Oliveira C, Save V, Carneiro F, Paterson AL, Grehan N, Dwerryhouse S, Lao-Sirieix P, Caldas C, Fitzgerald RC: Mechanisms and sequelae of E-cadherin silencing in hereditary diffuse gastric cancer. J Pathol; 2008 Nov;216(3):295-306
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Archival tumour material was analysed from 16 patients with CDH1 germline mutations and seven patients fulfilling HDGC criteria without CDH1 germline mutations.
  • Cadherin expression levels were determined by real-time RT-PCR and immunohistochemistry.
  • Tumours from 4/16 individuals had promoter hypermethylation that was restricted to the A allele haplotype in three cases.
  • E-cadherin loss (mRNA and protein) generally correlated with identification of a second hit.


14. Fu G, Liu M, Zeng W, Pu J, Bi Y, Ma G, Liu J: Establishment of a multiplex RT-PCR assay to detect different lineages of swine H1 and H3 influenza A viruses. Virus Genes; 2010 Oct;41(2):236-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of a multiplex RT-PCR assay to detect different lineages of swine H1 and H3 influenza A viruses.
  • The reverse transcriptase polymerase chain reaction (RT-PCR) assay is an effective method for use in influenza surveillance.
  • In this study, a multiplex RT-PCR method was developed for simultaneous identification of hemagglutinin (HA) genes derived from the three lineages of swine influenza viruses.
  • This multiplex RT-PCR method provides a rapid and specific swine influenza diagnostic tool that also has the potential for investigating the epidemiology of different lineages of swine influenza virus prevalent currently in China.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol Methods. 2002 Apr;102(1-2):53-9 [11879692.001]
  • [Cites] N Engl J Med. 2009 Jul 9;361(2):115-9 [19474418.001]
  • [Cites] Virus Genes. 2006 Jun;32(3):261-7 [16732478.001]
  • [Cites] Am J Vet Res. 1994 Jul;55(7):952-6 [7978634.001]
  • [Cites] J Clin Microbiol. 1991 Mar;29(3):470-4 [2037663.001]
  • [Cites] Biochem Biophys Res Commun. 2009 Aug 21;386(2):278-83 [19460353.001]
  • [Cites] J Clin Microbiol. 2009 Aug;47(8):2643-6 [19553585.001]
  • [Cites] Science. 2009 Jul 10;325(5937):197-201 [19465683.001]
  • [Cites] J Virol. 1998 Sep;72(9):7367-73 [9696833.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Apr 27;356(1):91-6 [17346674.001]
  • [Cites] N Engl J Med. 2009 Jun 18;360(25):2605-15 [19423869.001]
  • [Cites] Biochem Biophys Res Commun. 1990 Mar 16;167(2):425-30 [2322232.001]
  • [Cites] J Virol Methods. 2008 Jul;151(1):30-4 [18486976.001]
  • (PMID = 20700759.001).
  • [ISSN] 1572-994X
  • [Journal-full-title] Virus genes
  • [ISO-abbreviation] Virus Genes
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


15. Seddas PM, Arnould C, Tollot M, Arias CM, Gianinazzi-Pearson V: Spatial monitoring of gene activity in extraradical and intraradical developmental stages of arbuscular mycorrhizal fungi by direct fluorescent in situ RT-PCR. Fungal Genet Biol; 2008 Aug;45(8):1155-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spatial monitoring of gene activity in extraradical and intraradical developmental stages of arbuscular mycorrhizal fungi by direct fluorescent in situ RT-PCR.
  • To overcome this drawback, a direct fluorescent in situ RT-PCR methodology was developed for spatial mapping of gene expression in different presymbiotic and symbiotic structures of an arbuscular mycorrhizal fungus.
  • Transcript detection was optimized by targeting the LSU rRNA gene of Glomus intraradices and monitoring expression of a stearoyl-CoA-desaturase gene that is consistently expressed at high levels in spores, hyphae, arbuscules and vesicles.
  • Direct fluorescent in situ RT-PCR offers new perspectives for the sensitive analysis of fungal developmental processes that occur during functional differentiation in symbiotic arbuscular mycorrhiza interactions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18585067.001).
  • [ISSN] 1096-0937
  • [Journal-full-title] Fungal genetics and biology : FG & B
  • [ISO-abbreviation] Fungal Genet. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Fluorescent Dyes; 0 / Fungal Proteins; 0 / Xanthenes; 82354-19-6 / Texas red; EC 1.14.19.1 / Stearoyl-CoA Desaturase; EC 1.15.1.1 / Superoxide Dismutase; EC 5.2.1.8 / Peptidylprolyl Isomerase
  •  go-up   go-down


21. Troisi A, Orlandi G: Charge-transport regime of crystalline organic semiconductors: diffusion limited by thermal off-diagonal electronic disorder. Phys Rev Lett; 2006 Mar 3;96(8):086601
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We propose that the electron transport in crystalline organic semiconductors at room temperature (RT) is neither polaronic nor a combination of thermally activated hopping and polaronic transport, as previously thought.
  • This effect destroys the translational symmetry of the electronic Hamiltonian and makes the band description inadequate for RT organic crystals.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16606209.001).
  • [ISSN] 0031-9007
  • [Journal-full-title] Physical review letters
  • [ISO-abbreviation] Phys. Rev. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. DenBesten PK, Machule D, Zhang Y, Yan Q, Li W: Characterization of human primary enamel organ epithelial cells in vitro. Arch Oral Biol; 2005 Aug;50(8):689-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of human primary enamel organ epithelial cells in vitro.
  • The expression of enamel matrix proteins was analyzed by RT-PCR and cytokeratin 14 was detected by immunohistochemistry.
  • Amelogenin, ameloblastin, enamelin, MMP-20 and KLK-4 were detected in CAB cells by RT-PCR.

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15958200.001).
  • [ISSN] 0003-9969
  • [Journal-full-title] Archives of oral biology
  • [ISO-abbreviation] Arch. Oral Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AMBN protein, human; 0 / Amelogenin; 0 / Dental Enamel Proteins; 0 / Membrane Proteins; 0 / tuftelin; 68238-35-7 / Keratins; EC 3.4.21.- / Kallikreins; EC 3.4.21.- / kallikrein 4; EC 3.4.24.- / MMP20 protein, human; EC 3.4.24.- / Matrix Metalloproteinase 20; EC 3.4.24.- / Matrix Metalloproteinases; SY7Q814VUP / Calcium
  •  go-up   go-down


23. Phillips MD, Flynn MG, McFarlin BK, Stewart LK, Timmerman KL: Resistance training at eight-repetition maximum reduces the inflammatory milieu in elderly women. Med Sci Sports Exerc; 2010 Feb;42(2):314-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resistance training at eight-repetition maximum reduces the inflammatory milieu in elderly women.
  • We examined the influence of moderate- to high-intensity resistance trainings (RT) on inflammatory cytokines (interleukin 6 (IL-6) and 1beta (IL-1beta) and tumor necrosis factor alpha (TNF-alpha)) in circulation and lipopolysaccharide (LPS)-stimulated whole blood in elderly women.
  • Participants in the HRT, SER, and NHR groups trained (three sets, 10 exercises at eight-repetition maximum (8RM)) 3 d x wk(-1), whereas participants in the CON group maintained their "normal" activity for 10 wk.
  • Participants performed a bout of resistance exercise (RE at 8RM; HRT, SER, and NHR groups) or sat quietly (CON) before (BT) and after (AT) RT to assess the influence of training on the acute responses to RE.
  • Blood samples were obtained preexercise (PR), postexercise (PO), and 2 h postexercise (2H; same time points for resting CON).
  • RT significantly reduced resting serum TNF-alpha level by 37%.
  • RT also reduced LPS-stimulated production of IL-6, IL-1beta, and TNF-alpha at all time points (PR, PO, and 2H; per monocyte).
  • CONCLUSIONS: We found that 10 wk of moderate- to high-intensity RT 1) reduced the systemic inflammatory milieu and 2) abrogated exercise-induced circulating IL-6 in previously sedentary elderly women.
  • [MeSH-major] Interleukin-1beta / metabolism. Interleukin-6 / metabolism. Lipopolysaccharides / metabolism. Resistance Training. Tumor Necrosis Factor-alpha / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19927028.001).
  • [ISSN] 1530-0315
  • [Journal-full-title] Medicine and science in sports and exercise
  • [ISO-abbreviation] Med Sci Sports Exerc
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-1beta; 0 / Interleukin-6; 0 / Lipopolysaccharides; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


24. Thompson A, van der Slik AR, Koning F, van Bergen J: An improved RT-PCR method for the detection of killer-cell immunoglobulin-like receptor (KIR) transcripts. Immunogenetics; 2006 Nov;58(11):865-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An improved RT-PCR method for the detection of killer-cell immunoglobulin-like receptor (KIR) transcripts.
  • In this study, a reverse transcriptase-polymerase chain reaction (RT-PCR) that uses new primer sets for the gene-specific detection of KIR transcripts is presented and validated.
  • The key advantage of this RT-PCR method over previously published ones is that it was designed to detect transcripts of all confirmed allelic variants of the KIR genes, while remaining gene-specific.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunity. 1997 Dec;7(6):753-63 [9430221.001]
  • [Cites] J Immunol. 2001 Mar 1;166(5):2992-3001 [11207248.001]
  • [Cites] J Exp Med. 1995 Sep 1;182(3):875-84 [7650491.001]
  • [Cites] J Immunol. 2003 Sep 15;171(6):3056-63 [12960331.001]
  • [Cites] Tissue Antigens. 2000 Oct;56(4):313-26 [11098931.001]
  • [Cites] Nat Rev Immunol. 2005 Mar;5(3):201-14 [15719024.001]
  • [Cites] Tissue Antigens. 2004 Sep;64(3):226-34 [15304002.001]
  • [Cites] J Exp Med. 2004 Oct 18;200(8):957-65 [15477349.001]
  • [Cites] J Immunol. 2000 Jun 1;164(11):5797-804 [10820258.001]
  • [Cites] Science. 2004 Aug 6;305(5685):872-4 [15297676.001]
  • [Cites] J Exp Med. 2006 Mar 20;203(3):633-45 [16533882.001]
  • [Cites] Nat Genet. 2002 Aug;31(4):429-34 [12134147.001]
  • [Cites] Hum Immunol. 2004 Jun;65(6):602-12 [15219380.001]
  • [Cites] Immunity. 1997 Dec;7(6):739-51 [9430220.001]
  • [Cites] Hum Immunol. 2003 May;64(5):567-71 [12691708.001]
  • [Cites] Transplantation. 1999 Dec 15;68(11):1784-9 [10609957.001]
  • [Cites] Tissue Antigens. 2002 Sep;60(3):254-8 [12445308.001]
  • [Cites] J Immunol. 2004 Dec 1;173(11):6719-26 [15557164.001]
  • [Cites] Cancer Immunol Immunother. 2005 Feb;54(2):172-8 [15248031.001]
  • [Cites] J Exp Med. 2005 Apr 4;201(7):1069-75 [15809352.001]
  • [Cites] Tissue Antigens. 2004 Oct;64(4):462-8 [15361123.001]
  • [Cites] Curr Top Microbiol Immunol. 2006;298:1-21 [16329183.001]
  • [Cites] Hum Immunol. 2004 Jan;65(1):31-8 [14700593.001]
  • [Cites] J Immunol. 2002 Sep 15;169(6):2818-22 [12218090.001]
  • [Cites] J Exp Med. 2000 Oct 2;192(7):1059-68 [11015446.001]
  • [Cites] Immunology. 2002 Jul;106(3):373-80 [12100725.001]
  • [Cites] Tissue Antigens. 2002 Mar;59(3):184-93 [12074708.001]
  • [Cites] Immunogenetics. 2006 Jan;57(12):904-16 [16391939.001]
  • [Cites] Immunogenetics. 2003 Jul;55(4):227-39 [12838379.001]
  • [Cites] Hum Immunol. 2004 Jun;65(6):613-21 [15219381.001]
  • [Cites] J Immunol. 2003 Aug 15;171(4):1768-74 [12902476.001]
  • [Cites] Immunogenetics. 2001;52(3-4):195-205 [11220621.001]
  • [Cites] Immunogenetics. 2002 Mar;53(12):1009-19 [11904677.001]
  • [Cites] Eur J Immunol. 2004 Jun;34(6):1673-9 [15162437.001]
  • [Cites] Eur J Immunogenet. 2003 Jun;30(3):213-21 [12787000.001]
  • [Cites] J Immunol. 2000 Jul 15;165(2):1138-45 [10878393.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4778-83 [10781084.001]
  • [Cites] J Exp Med. 2001 May 21;193(10):1159-67 [11369787.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13224-9 [16141329.001]
  • [Cites] J Immunol. 2003 Nov 15;171(10):5396-405 [14607943.001]
  • [Cites] PLoS Biol. 2006 Jan;4(1):e9 [16366734.001]
  • [Cites] Eur J Immunol. 1998 Dec;28(12):3959-67 [9862332.001]
  • [Cites] Tissue Antigens. 2004 Aug;64(2):188-94 [15245374.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2673-7 [16284396.001]
  • [Cites] Diabetes. 2003 Oct;52(10):2639-42 [14514651.001]
  • (PMID = 17033821.001).
  • [ISSN] 0093-7711
  • [Journal-full-title] Immunogenetics
  • [ISO-abbreviation] Immunogenetics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / RNA, Messenger; 0 / Receptors, Immunologic; 0 / Receptors, KIR
  •  go-up   go-down


25. Mendenhall WM, Amdur RJ, Morris CG, Kirwan J, Malyapa RS, Vaysberg M, Werning JW, Mendenhall NP: Carcinoma of the nasal cavity and paranasal sinuses. Laryngoscope; 2009 May;119(5):899-906
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES/HYPOTHESIS: To determine the outcomes after radiotherapy (RT) alone or combined with surgery at the University of Florida for patients with carcinomas of the nasal cavity and paranasal sinuses.
  • Fifty-six patients were treated with definitive RT, and 53 patients received surgery and preoperative (eight patients) or postoperative (45 patients) RT.
  • Local control at 5 years was 43% after definitive RT versus 84% after surgery and adjuvant RT (P < .0001).
  • Multivariate analysis of local control revealed that both overall stage and treatment group (definitive RT versus surgery and adjuvant RT) significantly impacted this endpoint.
  • Cause-specific survival rates were: stages I to III, 81%; stage IV, 54%; and overall, 62%.
  • Thirty-one (20%) of 109 patients sustained severe complications; 17 of 56 patients (16%) after definitive RT and 14 of 53 patients (25%) after surgery and adjuvant RT.
  • CONCLUSIONS: The probability of local control and cause-specific survival is better after surgery and RT compared with definitive RT.
  • There is a modest increase in the risk of complications after surgery and RT.
  • Thus, the preferred treatment is surgery combined with preoperative or postoperative RT.
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Male. Nasal Cavity / pathology. Neoplasm Staging. Radiotherapy Dosage. Radiotherapy, Adjuvant. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19358246.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Levi JE, Wendel S, Takaoka DT, Silva IC, Castro JP, Torezan-Filho MA, Ghaname J, Gioachini R, Brandão J, Landi EP, Teixeira AC, Durigon EL: Replacement of HIV p24 Ag test by a multiplex RT-PCR method for primary screening of blood donors. Rev Inst Med Trop Sao Paulo; 2007 May-Jun;49(3):171-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Replacement of HIV p24 Ag test by a multiplex RT-PCR method for primary screening of blood donors.
  • Nucleic Acid Testing (NAT) as a tool for primary screening of blood donors became a reality in the end of the 1990 decade.
  • We report here the development of an "in-house" RT-PCR method that allows the simultaneous (multiplex) detection of HCV and HIV-RNA in addition to an artificial RNA employed as an external control.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Blood Transfusion and Donation.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17625695.001).
  • [ISSN] 0036-4665
  • [Journal-full-title] Revista do Instituto de Medicina Tropical de São Paulo
  • [ISO-abbreviation] Rev. Inst. Med. Trop. Sao Paulo
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / HIV Core Protein p24; 0 / RNA, Viral
  •  go-up   go-down


27. Moldenhauer A, Wolf J, Habermann G, Genter G, Kiesewetter H, Salama A: Optimum storage conditions for cord blood-derived hematopoietic progenitor cells prior to isolation. Bone Marrow Transplant; 2007 Nov;40(9):837-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We therefore evaluated CD34+ cells isolated from cord blood units (n=57) within 1 h after collection and following storage for 24, 48 and 72 h at either room temperature (RT) or 4 degrees C.
  • After 48 h, the number of CD34+ cells increased compared to 24 h, if the cord blood had been stored at RT resulting in almost three times more CD34+ cells than at 4 degrees C.
  • These cells had a lower early apoptosis rate and formed four times more BFU-E than those stored at 4 degrees C with equivalent plating efficiencies.
  • CD34+ cells kept at RT for 48 h had the highest transmigration capacities, which paralleled an increased CXCR-4 expression.
  • Cord blood should be stored at RT before CD34+ isolation and a storage time for 48 h should be preferred to 24 h.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17768391.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


28. Choo R, Pearse M, Danjoux C, Gardner S, Morton G, Szumacher E, Loblaw DA, Cheung P: Analysis of gastrointestinal and genitourinary morbidity of postoperative radiotherapy for pathologic T3 disease or positive surgical margins after radical prostatectomy using national cancer institute expanded common toxicity criteria. Int J Radiat Oncol Biol Phys; 2008 Nov 15;72(4):989-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate the acute and late gastrointestinal (GI) and genitourinary (GU) toxicity of postoperative radiotherapy (RT) after radical prostatectomy (RP).
  • METHODS AND MATERIALS: A total of 78 patients with pT3 or positive surgical margins after RP were treated with RT plus 2 years of androgen suppression, according to a Phase II study.
  • The median interval between RP and postoperative RT was 4.2 months.
  • Of these patients, 66%, 29%, and 1% experienced Grade 1, 2, and 3 acute GI or GU toxicity, respectively.
  • The cumulative incidence of Grade 2 or greater and Grade 3 or greater late GI toxicity at 36 months was 8.1% and 0%, respectively.
  • The cumulative incidence of Grade 2 or greater and Grade 3 or greater late GU toxicity at 36 months was 16.4% and 2.7%, respectively.
  • None had Grade 4 or greater late toxicity.
  • The severity of acute GU toxicity (less than Grade 2 vs. Grade 2 or greater) was a significant predictor factor for Grade 2 or greater late GU toxicity after adjusting for pre-existing GU dysfunction.
  • CONCLUSIONS: Postoperative RT was generally well tolerated.
  • Grade 3 or greater late GI or GU toxicity was uncommon.
  • [MeSH-major] Gastrointestinal Diseases / etiology. Male Urogenital Diseases / etiology. Neoplasm Recurrence, Local / prevention & control. Prostatectomy. Prostatic Neoplasms / radiotherapy. Prostatic Neoplasms / surgery. Radiation Injuries / etiology. Radiotherapy, Adjuvant / adverse effects

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18436391.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


29. Hirano S, Tateya I, Kitamura M, Kada S, Ishikawa S, Kanda T, Tanaka S, Ito J: Ten years single institutional experience of treatment for advanced hypopharyngeal cancer in Kyoto University. Acta Otolaryngol Suppl; 2010 Nov;(563):56-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Induction chemotherapy has the potential to extend organ preservation therapy even in cases with locally advanced primary lesion.
  • It is also important to develop a strategy to reduce distant metastasis and to keep track of second primary cancers.
  • METHODS: A total of 72 cases with stage III/IV hypopharyngeal cancer were treated at Kyoto University Hospital during 2000-2008.
  • Surgery was performed in 56 cases; total pharyngolaryngoesophagectomy (TPLE) in 39 cases and partial pharyngectomy (PPX) preserving the larynx in 17 cases.
  • Radiotherapy (RT) with or without concurrent chemotherapy was applied in 16 cases.
  • DSS rates in cases treated with surgery and those with RT were 65.1% and 56.1%, respectively.
  • Local control rates for cases treated with TPLE, PPX, and RT were 97.3%, 100%, and 80.4%, respectively.
  • In the end, 17 cases died of the primary disease, while 10 cases died of other causes, mainly second primary cancers.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Combined Modality Therapy. Female. Hospitals, University. Humans. Japan. Male. Middle Aged. Neoplasm Staging. Pharyngectomy. Retrospective Studies. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • Genetic Alliance. consumer health - TEN.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20879820.001).
  • [ISSN] 0365-5237
  • [Journal-full-title] Acta oto-laryngologica. Supplementum
  • [ISO-abbreviation] Acta Otolaryngol Suppl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


30. Wo JY, Taghian AG, Nguyen PL, Raad RA, Sreedhara M, Bellon JR, Wong JS, Gadd MA, Smith BL, Harris JR: The association between biological subtype and isolated regional nodal failure after breast-conserving therapy. Int J Radiat Oncol Biol Phys; 2010 May 1;77(1):188-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate the risk of isolated regional nodal failure (RNF) among women with invasive breast cancer treated with breast-conserving surgery (BCS) and radiation therapy (RT) and to determine factors, including biological subtype, associated with RNF.
  • METHODS AND MATERIALS: We retrospectively studied 1,000 consecutive women with invasive breast cancer who received breast-conserving surgery and RT from 1997 through 2002.
  • Biological subtype classification into luminal A, luminal B, HER-2, and basal subtypes was based on estrogen receptor status-, progesterone receptor status-, and HER-2-status of the primary tumor.
  • On univariate analysis, biological subtype (p = 0.0002), lymph node involvement (p = 0.008), lymphovascular invasion (p = 0.02), and Grade 3 histology (p = 0.01) were associated with significantly higher RNF rates.
  • Low rates of RNF in patients with one to three positive nodes suggest that tangential RT without RNI is reasonable in most patients.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Lymph Node Excision. Lymph Nodes / pathology. Lymphatic Irradiation. Mastectomy, Segmental. Neoplasm Invasiveness. Prognosis. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Retrospective Studies. Risk. Sentinel Lymph Node Biopsy / utilization

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20171798.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


31. MacDonald TJ, Arenson EB, Ater J, Sposto R, Bevan HE, Bruner J, Deutsch M, Kurczynski E, Luerssen T, McGuire-Cullen P, O'Brien R, Shah N, Steinbok P, Strain J, Thomson J, Holmes E, Vezina G, Yates A, Phillips P, Packer R: Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma: final analysis of Children's Cancer Group Study 9933. Cancer; 2005 Dec 15;104(12):2862-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma: final analysis of Children's Cancer Group Study 9933.
  • BACKGROUND: High-grade astrocytomas (HGA) carry a dismal prognosis and compose nearly 20% of all childhood brain tumors.
  • METHODS: In a nationwide study, The Children's Cancer Group (CCG) prospectively evaluated 102 children with HGA and postoperative residual disease for efficacy and toxicity of four courses of HDCT before radiotherapy (RT).
  • After HDCT, all patients were to receive local RT followed by lomustine and vincristine.
  • Twenty-six patients were excluded after central neuroradiographic review (n = 8) or pathology review (n = 18).
  • Nonhematologic serious toxicities were common (29%), and 21% of patients did not receive RT.
  • Median time to an event was longest for Regimen A (283 days compared with 83 and 91 days for Regimens B and C, respectively).
  • CONCLUSIONS: OS and EFS were not affected by histologic grade.
  • Patients who responded to HDCT had a nominally higher survival rate (P = 0.03 for trend).
  • The authors conclude that these commonly used HDCT regimens provide no additional clinical benefit to conventional treatment in HGA, regardless of the amount of measurable residual tumor.
  • [MeSH-minor] Adolescent. Adult. Brain Stem Neoplasms / drug therapy. Brain Stem Neoplasms / mortality. Brain Stem Neoplasms / pathology. Brain Stem Neoplasms / radiotherapy. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Neoplasm Staging. Probability. Prognosis. Prospective Studies. Radiotherapy, High-Energy. Reference Values. Risk Assessment. Spinal Cord Neoplasms / drug therapy. Spinal Cord Neoplasms / mortality. Spinal Cord Neoplasms / pathology. Spinal Cord Neoplasms / radiotherapy. Survival Analysis. Time Factors. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 16315242.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


32. Katz MS, Efstathiou JA, D'Amico AV, Kattan MW, Sanda MG, Nguyen PL, Smith MR, Carroll PR, Zietman AL: The 'CaP Calculator': an online decision support tool for clinically localized prostate cancer. BJU Int; 2010 May;105(10):1417-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Estimates of the prostate-specific antigen (PSA) outcome after radical prostatectomy (RP) or radiotherapy (RT), and clinical outcomes after RT, were also entered.
  • The 5-year estimates of PSA relapse-free survival after RT and 10-year estimates after RP were available.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2003 Aug;127(8):1007-8 [12873176.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):621-8 [14529765.001]
  • [Cites] J Urol. 2003 Nov;170(5):1798-803 [14532779.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):915-28 [14575822.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 1):2306-10 [14634402.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4568-71 [14673043.001]
  • [Cites] Urology. 2004 Apr;63(4):751-6 [15072894.001]
  • [Cites] J Urol. 2004 Jun;171(6 Pt 1):2215-20 [15126788.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jan 1;28(1):33-7 [7505775.001]
  • [Cites] Urology. 1995 Jan;45(1):70-4 [7529449.001]
  • [Cites] JAMA. 1997 May 14;277(18):1445-51 [9145716.001]
  • [Cites] J Urol. 1998 Jun;159(6):2023-9 [9598511.001]
  • [Cites] J Natl Cancer Inst. 1998 May 20;90(10):766-71 [9605647.001]
  • [Cites] JAMA. 1998 Sep 16;280(11):969-74 [9749478.001]
  • [Cites] J Urol. 2005 Jun;173(6):1938-42 [15879786.001]
  • [Cites] Urology. 2003 Mar;61(3):589-95 [12639653.001]
  • [Cites] BJU Int. 2003 Jan;91(1):14-7 [12614242.001]
  • [Cites] Urology. 2001 Sep;58(3):393-9 [11549487.001]
  • [Cites] Eur J Cancer. 2001 May;37(7):884-91 [11313177.001]
  • [Cites] J Clin Oncol. 2000 Oct 1;18(19):3352-9 [11013275.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(15):2862-8 [10920134.001]
  • [Cites] BMJ. 1999 Nov 6;319(7219):1241-7 [10550090.001]
  • [Cites] J Natl Cancer Inst. 2006 May 17;98(10):715-7 [16705126.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):104-9 [19286330.001]
  • [Cites] Cancer. 2007 Nov 15;110(10):2210-7 [17893907.001]
  • [Cites] Urology. 2007 Jun;69(6):1095-101 [17572194.001]
  • [Cites] Clin Genitourin Cancer. 2006 Dec;5(3):219-26 [17239276.001]
  • [Cites] BJU Int. 2006 Oct;98(4):788-93 [16796698.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74 [16798415.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):975-81 [16750319.001]
  • (PMID = 20346051.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K24 CA121990; United States / NCI NIH HHS / CA / K24 CA121990-05
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 30
  • [Other-IDs] NLM/ NIHMS272528; NLM/ PMC3090683
  •  go-up   go-down


33. Salzmann GM, Paul J, Bauer JS, Woertler K, Sauerschnig M, Landwehr S, Imhoff AB, Schöttle PB: T2 assessment and clinical outcome following autologous matrix-assisted chondrocyte and osteochondral autograft transplantation. Osteoarthritis Cartilage; 2009 Dec;17(12):1576-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While previous clinical studies have compared the respective outcome, there is no such information investigating the ultrastructural composition using T2 mapping comparing cartilage T2 values of the repair tissue (RT).
  • RESULTS: Global T2 values of healthy femoral cartilage (HC) were similar among groups, while T2 values of the RT following MACT (46.8ms, SD 8.6) were significantly lower when compared to RT T2 values after OCT (55.5ms, SD 6.7) (P=0.048).

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19737529.001).
  • [ISSN] 1522-9653
  • [Journal-full-title] Osteoarthritis and cartilage
  • [ISO-abbreviation] Osteoarthr. Cartil.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


34. Bai J, Lü Y, Bai Q: Construction of porcine CCK pDNA and its expression in COS-7 cells. J Huazhong Univ Sci Technolog Med Sci; 2007 Jun;27(3):278-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Total RNA was extracted from porcine intestinal mucosa.
  • RT-PCR was used to amplify the aimed segments CCKcDNA which was then digested with EcoR1 and BamH1 and inserted into a eukaryotic expression plasmid pIRES2-EGFP to construct CCK pDNA.
  • The expression of CCK in transfected COS-7 cells was detected 24, 48 and 72 h post-transfection with fluorescence microscopy and the expression level of CCK mRNA in transfected COS-7 cells was assayed by using RT-PCR.
  • The expression of CCK mRNA in the cells was detectable by using RT-PCR.
  • It was concluded CCK pDNA was expressed successfully in COS-7 cells, which lays a foundation for further research on the relationship between CCK and tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 1996 Apr 1;383(3):241-4 [8925905.001]
  • [Cites] Biochim Biophys Acta. 2004 Jul 6;1704(1):1-10 [15238241.001]
  • [Cites] Immunol Today. 1998 Feb;19(2):89-97 [9509764.001]
  • [Cites] Minerva Chir. 2004 Apr;59(2):99-111 [15238885.001]
  • [Cites] Anticancer Drugs. 2002 Mar;13(3):229-35 [11984066.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1284-90 [12684396.001]
  • [Cites] J Clin Invest. 1998 Sep 15;102(6):1258-64 [9739060.001]
  • [Cites] J Am Coll Surg. 1998 Oct;187(4):429-42 [9783792.001]
  • [Cites] Int J Oncol. 1999 Jun;14(6):1129-35 [10339669.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jan;86(1):251-8 [11232009.001]
  • (PMID = 17641841.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / RNA, Messenger; 0 / Recombinant Fusion Proteins; 147336-22-9 / Green Fluorescent Proteins; 9011-97-6 / Cholecystokinin
  •  go-up   go-down


35. Hulmi JJ, Tannerstedt J, Selänne H, Kainulainen H, Kovanen V, Mero AA: Resistance exercise with whey protein ingestion affects mTOR signaling pathway and myostatin in men. J Appl Physiol (1985); 2009 May;106(5):1720-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resistance exercise with whey protein ingestion affects mTOR signaling pathway and myostatin in men.
  • The effects of whey protein ingestion on acute and long-term signaling responses of resistance exercise are not well known.
  • Vastus lateralis (VL) muscle biopsies were taken before and 1 h and 48 h after a leg press of 5 x 10 repetitions [resistance exercise (RE)] and after 21 wk (2 times per week) of resistance training (RT).
  • Protein (15 g of whey) or nonenergetic placebo was ingested before and after a single RE bout and each RE workout throughout the RT.
  • Mammalian target of rapamycin (mTOR) phosphorylation was increased after the RE bout and RT only in the protein group, whereas the protein ingestion prevented the post-RE decrease in phosphorylated eukaryotic initiation factor 4E binding protein 1 (p-4E-BP1).
  • Akt phosphorylation decreased after RT, whereas no change was observed in phosphorylated eukaryotic elongation factor 2.
  • The results indicate that resistance exercise rapidly increases mTOR signaling and may decrease myostatin protein expression in muscle and that whey protein increases and prolongs the mTOR signaling response.


36. Rödel F, Keilholz L, Herrmann M, Weiss C, Frey B, Voll R, Gaipl U, Rödel C: Activator protein 1 shows a biphasic induction and transcriptional activity after low dose X-irradiation in EA.hy.926 endothelial cells. Autoimmunity; 2009 May;42(4):343-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Low dose radiotherapy (LD-RT) is known to exert an anti-inflammatory effect.
  • We have recently shown that LD-RT of stimulated EA.hy.926 endothelial cells (EC) resulted in a biphasic DNA-binding and transcriptional activity of NF-kappaB in parallel with a biphasic course of leukocyte adhesion.
  • In conclusion, the discontinuous dose response of AP-1 activation may add a further facet to the plethora of mechanisms contributing to the anti-inflammatory efficacy of LD-RT.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19811296.001).
  • [ISSN] 1607-842X
  • [Journal-full-title] Autoimmunity
  • [ISO-abbreviation] Autoimmunity
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Transcription Factor AP-1
  •  go-up   go-down


37. Hoskin PJ, Rojas AM, Bentzen SM, Saunders MI: Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol; 2010 Nov 20;28(33):4912-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Phase II clinical studies suggest that hypoxic modification with carbogen and nicotinamide (CON) may increase the efficacy of radiotherapy (RT).
  • PATIENTS AND METHODS: Three hundred thirty-three patients with locally advanced bladder carcinoma were randomly assigned to RT alone versus RT with CON.
  • The primary end point was cystoscopic control at 6 months (CC(6m)) and secondary end points were overall survival (OS), local relapse-free survival (RFS), urinary and rectal morbidity.
  • RESULTS: CC(6m) was 81% for RT + CON and 76% for RT alone (P = .3); however, just more than half of patients underwent cystoscopy at that time.
  • Three-year estimates of OS were 59% and 46% (P = .04) and 3-year estimates of RFS were 54% and 43% (P = .06) for RT + CON versus RT alone.
  • Risk of death was 14% lower with RT + CON (P = .04).
  • In multivariate comparison, RT + CON significantly reduced the risk of relapse (P = .05) and death (P = .03).
  • CONCLUSION: RT + CON produced a small nonsignificant improvement in CC(6m).
  • Differences in OS, risk of death, and local relapse were significantly in favor of RT + CON.
  • Results indicate a benefit of adding CON to radical RT.
  • [MeSH-minor] Aged. Aged, 80 and over. Cystectomy. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carbon dioxide .
  • Hazardous Substances Data Bank. OXYGEN .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Rev Clin Oncol. 2011 Mar;8(3):129-30 [21283126.001]
  • (PMID = 20956620.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; 142M471B3J / Carbon Dioxide; 25X51I8RD4 / Niacinamide; 8063-77-2 / carbogen; S88TT14065 / Oxygen
  •  go-up   go-down


38. Sanguineti G, Richetti A, Bignardi M, Corvo' R, Gabriele P, Sormani MP, Antognoni P: Accelerated versus conventional fractionated postoperative radiotherapy for advanced head and neck cancer: results of a multicenter Phase III study. Int J Radiat Oncol Biol Phys; 2005 Mar 1;61(3):762-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accelerated versus conventional fractionated postoperative radiotherapy for advanced head and neck cancer: results of a multicenter Phase III study.
  • PURPOSE: To determine whether, in the postoperative setting, accelerated fractionation (AF) radiotherapy (RT) yields a superior locoregional control rate compared with conventional fractionation (CF) RT in locally advanced squamous cell carcinomas of the oral cavity, oropharynx, larynx, or hypopharynx.
  • METHODS AND MATERIALS: Patients from four institutions with one or more high-risk features (pT4, positive resection margins, pN >1, perineural/lymphovascular invasion, extracapsular extension, subglottic extension) after surgery were randomly assigned to either RT with one daily session of 2 Gy up to 60 Gy in 6 weeks or AF.
  • Accelerated fractionation consisted of a "biphasic concomitant boost" schedule, with the boost delivered during the first and last weeks of treatment, to deliver 64 Gy in 5 weeks.
  • The primary endpoint of the study was locoregional control.
  • However, interaction analysis with median values as cut-offs showed a trend for improved locoregional control for those patients who had a delay in starting RT and who were treated with AF compared with those with a similar delay but who were treated with CF (hazard ratio = 0.5, 95% confidence interval 0.2-1.1).
  • Although preliminary, actuarial Grade 3+ late toxicity estimates at 2 years were 18% +/- 4% and 27% +/- 6% for CF and AF, respectively (p = 0.10).
  • CONCLUSION: Accelerated fractionation does not seem to be worthwhile for squamous cell carcinoma of the head and neck after resection; however, AF might be an option for patients who delay starting RT.

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15708255.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


39. Ross LL, Weinberg WG, DeJesus E, Fischl MA, Horton JH, Pappa KA, Lancaster CT, Pakes GE, Smith KY: Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients. AIDS Res Hum Retroviruses; 2010 Apr;26(4):407-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Population genotyping (PG) can underestimate resistance if resistance-containing low abundance variants go undetected.
  • VF was defined as confirmed HIV-1 RNA > or =400 copies/ml at > or =24 weeks or viral rebound >400 copies/ml any time following viral suppression.
  • Baseline resistance mutations were more prevalent in patients receiving FPV/r (10/53) than ATV/r (3/53).
  • In the four FPV/r-treated VFs, baseline HIV TAMs combinations and/or PI mutations were detected in one by PG at VF (RT: L210W + T215C; PR: M46I + L76V) and three others by CA alone (RT: L210W + T215Y; RT: M41L; RT: K65R + K70R; PR: I47V); all four had study drug-associated mutations (CA detecting more HIV-1 resistance mutations than PG).
  • In the three ATV/r VFs, no baseline drug-associated mutations were detected by PG; for one patient CA detected RT: K65R; PR: I84V.
  • Phylogenetic analysis revealed tight clustering for FPV/r-treated VFs with highly related clones, whereas HIV-1 from ATV/r-treated VFs had no outgrowth from baseline of low abundance resistance-containing variants.
  • In conclusion, low-abundance HIV resistance-containing variants were detected in baseline samples from patients with VF.
  • Despite this and a baseline resistance imbalance between the two arms, FPV/r and ATV/r provided similar virologic suppression through 48 weeks; however, these findings highlight the necessity for the development of quick and inexpensive methods for detection of minority species to better guide therapy selection.
  • [MeSH-minor] Adolescent. Adult. Aged. Atazanavir Sulfate. Drug Administration Schedule. Drug Resistance, Multiple, Viral / genetics. Drug Therapy, Combination. Emtricitabine. Humans. Middle Aged. RNA, Viral / analysis. RNA, Viral / genetics. Sequence Analysis, RNA / methods. Tenofovir. Treatment Failure

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] PLoS Med. 2006 Sep;3(9):e356 [16984218.001]
  • [Cites] AIDS Res Hum Retroviruses. 2009 Apr;25(4):395-403 [19320570.001]
  • [Cites] Mol Biol Evol. 2007 Aug;24(8):1596-9 [17488738.001]
  • [Cites] Brief Bioinform. 2008 Jul;9(4):299-306 [18417537.001]
  • [Cites] HIV Clin Trials. 2008 May-Jun;9(3):152-63 [18547902.001]
  • [Cites] Clin Infect Dis. 2008 Jul 15;47(2):266-85 [18549313.001]
  • [Cites] PLoS Med. 2008 Jul 29;5(7):e158 [18666824.001]
  • [Cites] PLoS Med. 2008 Jul 29;5(7):e164 [18666826.001]
  • [Cites] JAMA. 2008 Aug 6;300(5):555-70 [18677028.001]
  • [Cites] Lancet. 2008 Aug 23;372(9639):646-55 [18722869.001]
  • [Cites] HIV Clin Trials. 2008 Jul-Aug;9(4):213-24 [18753116.001]
  • [Cites] Top HIV Med. 2008 Dec;16(5):138-45 [19106428.001]
  • [Cites] J Infect Dis. 2009 Mar 1;199(5):693-701 [19210162.001]
  • [Cites] Antimicrob Agents Chemother. 2009 Apr;53(4):1670-2 [19171798.001]
  • [Cites] AIDS. 2007 Jan 11;21(2):215-23 [17197813.001]
  • (PMID = 20380480.001).
  • [ISSN] 1931-8405
  • [Journal-full-title] AIDS research and human retroviruses
  • [ISO-abbreviation] AIDS Res. Hum. Retroviruses
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Carbamates; 0 / Oligopeptides; 0 / Organophosphates; 0 / Organophosphonates; 0 / Pyridines; 0 / RNA, Viral; 0 / Sulfonamides; 0W860991D6 / Deoxycytidine; 4MT4VIE29P / Atazanavir Sulfate; 99YXE507IL / Tenofovir; G70B4ETF4S / Emtricitabine; JAC85A2161 / Adenine; O3J8G9O825 / Ritonavir; WOU1621EEG / fosamprenavir
  • [Other-IDs] NLM/ PMC2875981
  •  go-up   go-down


40. Aradaib IE: PCR detection of African horse sickness virus serogroup based on genome segment three sequence analysis. J Virol Methods; 2009 Jul;159(1):1-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A nested reverse transcriptase (RT) polymerase chain reaction (RT-PCR), for rapid detection of African horse sickness virus (AHSV) double-stranded ribonucleic acid (dsRNA) in cell culture and tissue samples, was developed and evaluated.
  • Using an outer pair of primers (P1 and P2), selected from genome segment three of AHSV serotype 6 (AHSV-6), the RT-PCR-based assay resulted in amplification of a 890 base pair (bp) primary PCR product.
  • RNAs from the nine vaccine strains of AHSV, and a number of AHSV field isolates including the Central African isolates of AHSV-9 and AHSV-6, propagated in cell cultures, were detected by this assay.
  • The RT-PCR described below detected as little as 0.1 fg of AHSV RNA, which is equivalent to six viral particles.
  • The nested amplification confirmed the integrity of the primary PCR product and increased the sensitivity of the PCR assay by at least 1000-fold.
  • Application of this RT-PCR assay to clinical samples resulted in direct detection of AHSV dsRNA from blood and a variety of tissue samples collected from equines infected experimentally and naturally.
  • The specificity studies indicated that the primary or the nested PCR products were not amplified from, closely related orbiviruses including, bluetongue virus (BTV) prototypes serotypes 1, 2, 4, 10, 16 and 17; epizootic hemorrhagic disease of deer virus (EHDV) prototypes serotypes 1 and 2; EHDV-318, Sudanese isolates of palyam serogroup of orbiviruses; total nucleic acid extracts from uninfected Vero cells; or unfractionated blood from horses and donkeys that were AHSV-seronegative and virus isolation negative.
  • The RT-PCR provides a valuable tool for study of the epidemiology of AHSV and can be recommended for rapid diagnosis during an outbreak of the disease among susceptible equines.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19442836.001).
  • [ISSN] 1879-0984
  • [Journal-full-title] Journal of virological methods
  • [ISO-abbreviation] J. Virol. Methods
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA Primers; 0 / RNA, Viral
  •  go-up   go-down


41. Kawakami T, Terakawa Y, Tsuruno T, Murata T, Nishio A, Ohata K: Mechanical clot disruption following intravenous recombinant tissue plasminogen activator administration in non-responders. Neurol Med Chir (Tokyo); 2010;50(3):183-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The efficacy of selecting non-responders to intravenous recombinant tissue plasminogen activator (rt-PA) for mechanical clot disruption (MCD) was investigated based on cerebral angiography in the acute stage following rt-PA therapy. rt-PA therapy using 0.6 mg/kg was performed in eligible patients within 3 hours of onset.
  • Patients who did not show recanalization on cerebral angiography 1 hour after rt-PA initiation immediately underwent MCD.
  • Eighteen patients were initially treated with intravenous rt-PA, with mean time from stroke onset to rt-PA therapy of 120 +/- 27 minutes.
  • Time to recanalization by percutaneous transluminal angioplasty from stroke onset was 258 +/- 59 minutes.
  • MCD for non-responders determined by cerebral angiography at the end of intravenous rt-PA infusion can decrease the time to recanalization and improve recanalization rates, leading to good clinical outcome after acute stroke.
  • [MeSH-minor] Acute Disease. Aged. Aged, 80 and over. Brain Ischemia / therapy. Cerebral Angiography. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Injections, Intravenous. Male. Middle Aged. Patient Selection. Recombinant Proteins. Time Factors. Treatment Failure. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stroke.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20339266.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Fibrinolytic Agents; 0 / Recombinant Proteins; EC 3.4.21.68 / Tissue Plasminogen Activator
  •  go-up   go-down


42. Bergin PF, Doppelt JD, Hamilton WG, Mirick GE, Jones AE, Sritulanondha S, Helm JM, Tuan RS: Detection of periprosthetic infections with use of ribosomal RNA-based polymerase chain reaction. J Bone Joint Surg Am; 2010 Mar;92(3):654-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have reported the development of a messenger RNA (mRNA)-based procedure to reduce these false-positive results.
  • The limitations of this procedure are the lack of a universal target and reduced sensitivity due to a low concentration of bacterial mRNAs in test samples.
  • The objective of the present study was to determine whether reverse transcription-quantitative polymerase chain reaction (RT-qPCR) using universal primers can be used to detect the more abundant bacterial ribosomal RNA (rRNA) as an indicator of periprosthetic infection.
  • METHODS: Serial dilutions of simulated synovial fluid infections were analyzed with rRNA RT-qPCR to determine the detection limit of this assay.
  • Escherichia coli cultures treated with gentamicin were analyzed with RT-qPCR over a twenty-day time course to determine the degradation of rRNA as compared with the decrease in the viable cell count as determined by means of cell plating.
  • Sixty-four patients with a symptomatic effusion at the site of a total knee arthroplasty were enrolled, and complete patient information was documented in a prospective manner.
  • Synovial fluid analysis with rRNA RT-qPCR was performed in a blind fashion.
  • RESULTS: The rRNA RT-qPCR assay was able to detect as few as 590 colony forming units/mL of Staphylococcus aureus and 2900 colony forming units/mL of Escherichia coli.
  • The rRNA RT-qPCR signal closely followed cell death, pointing to its potential use as a viability marker.
  • Clinically, the test correctly identified all six patients with a confirmed infection and all fifty patients who clearly did not have an infection.
  • Infection was indicated by rRNA RT-qPCR in three of these patients who had elevated synovial fluid white blood-cell counts but negative results on culture.
  • For statistical purposes, all patients who were categorized as indeterminate were considered to have an infection for the purpose of analysis, for a prevalence of 22% in this cohort.
  • CONCLUSIONS: With respect to current diagnostic tests, rRNA-based RT-qPCR demonstrated 100% specificity and positive predictive value with a sensitivity equivalent to that of intraoperative culture.
  • The RT-qPCR signal followed bacterial culture trends but exhibited detectable level for seven days after sterilization, allowing for the detection of infection after the antibiotic administration.
  • These findings indicate that rRNA RT-qPCR is a sensitive and reliable test that retains the universal detection and speciation of DNA-based methods while functioning as a viability indicator.

  • MedlinePlus Health Information. consumer health - Bacterial Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Am. 2007 Jun;89(6):1298-305 [17545434.001]
  • [Cites] J Bone Joint Surg Am. 1983 Oct;65(8):1087-98 [6630253.001]
  • [Cites] J Arthroplasty. 2007 Sep;22(6 Suppl 2):94-9 [17823025.001]
  • [Cites] Clin Orthop Relat Res. 2007 Nov;464:146-50 [18062048.001]
  • [Cites] J Bone Joint Surg Am. 2008 Mar;90(3):602-8 [18310711.001]
  • [Cites] Clin Orthop Relat Res. 1989 Nov;(248):57-60 [2805496.001]
  • [Cites] AJR Am J Roentgenol. 1994 Aug;163(2):377-80 [8037035.001]
  • [Cites] Antimicrob Agents Chemother. 1994 Sep;38(9):1959-65 [7529012.001]
  • [Cites] Clin Orthop Relat Res. 1996 Oct;(331):11-22 [8895614.001]
  • [Cites] Clin Orthop Relat Res. 1997 Dec;(345):8-16 [9418615.001]
  • [Cites] Appl Environ Microbiol. 1998 Apr;64(4):1313-8 [9546166.001]
  • [Cites] J Bone Joint Surg Am. 1999 May;81(5):672-83 [10360695.001]
  • [Cites] J Clin Microbiol. 1999 Oct;37(10):3281-90 [10488193.001]
  • [Cites] Clin Orthop Relat Res. 2004 Dec;(429):188-92 [15577486.001]
  • [Cites] J Clin Microbiol. 2006 Mar;44(3):1018-28 [16517890.001]
  • [Cites] Environ Microbiol. 2006 Apr;8(4):658-66 [16584477.001]
  • [Cites] J Bone Joint Surg Am. 2006 Apr;88(4):869-82 [16595481.001]
  • [Cites] Clin Orthop Relat Res. 2006 May;446:45-50 [16672871.001]
  • [Cites] Antimicrob Agents Chemother. 2006 Jun;50(6):1913-20 [16723545.001]
  • [Cites] J Microbiol Methods. 2007 May;69(2):330-9 [17391789.001]
  • [Cites] Ann Rheum Dis. 2001 Mar;60(3):275-7 [11171691.001]
  • [Cites] Clin Orthop Relat Res. 2002 Nov;(404):125-31 [12439250.001]
  • [Cites] Clin Orthop Relat Res. 2003 Sep;(414):89-94 [12966281.001]
  • [Cites] J Arthroplasty. 2003 Dec;18(8):1038-43 [14658109.001]
  • [Cites] Scand J Infect Dis. 2004;36(6-7):410-6 [15307559.001]
  • [Cites] J Bone Joint Surg Am. 2007 Jul;89(7):1409-16 [17606776.001]
  • (PMID = 20194324.001).
  • [ISSN] 1535-1386
  • [Journal-full-title] The Journal of bone and joint surgery. American volume
  • [ISO-abbreviation] J Bone Joint Surg Am
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / Z01 AR041131; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Ribosomal; 9007-41-4 / C-Reactive Protein
  • [Other-IDs] NLM/ PMC2827826
  •  go-up   go-down


43. Aggarwal A, Singh M: Changes in skin and rectal temperature in lactating buffaloes provided with showers and wallowing during hot-dry season. Trop Anim Health Prod; 2008 Apr;40(3):223-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All the buffaloes were kept under loose housing system and were provided ad lib green maize fodder and water to drink during 30 days experiment during the month of August-September.
  • Showering group (SG) buffaloes were kept under water showers from 11:00 A.M. to 4:00 P.M., while wallowing group (WG) buffaloes were allowed to wallow in a water pond during the same time.
  • Physiological responses viz. rectal temperature (RT), respiration rate (RR), pulse rate (PR) and skin temperature (ST) were recorded before (8.00 A.M.) and after (4.00 P.M.) showers or wallowing.
  • Further, skin temperature of neck, head, udder, udder vein and RT varied (P < 0.01) in SG and WG buffaloes during periods of study.
  • The correlation data indicated a positive correlation of maximum air temperature with RT in SG but correlation was non-significant in WG.
  • RT was positively correlated with ST in SG (P < 0.05) and WG (P < 0.01).
  • The pooled data analysis of both groups also indicated a positive correlation of maximum temperature with RT (P < 0.05).

  • Hazardous Substances Data Bank. Water .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18484125.001).
  • [ISSN] 0049-4747
  • [Journal-full-title] Tropical animal health and production
  • [ISO-abbreviation] Trop Anim Health Prod
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 059QF0KO0R / Water
  •  go-up   go-down


44. Goodwin A, Parker S, Ghersi D, Wilcken N: Post-operative radiotherapy for ductal carcinoma in situ of the breast. Cochrane Database Syst Rev; 2009;(1):CD000563
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The addition of radiotherapy (RT) following breast conserving surgery (BCS) was first shown to reduce the risk of ipsilateral recurrence in the treatment of invasive breast cancer.
  • Randomised controlled trials (RCTs) have shown that RT can reduce the risk of recurrence, but assessment of potential long-term complications from addition of RT following BSC for DCIS has not been reported for women participating in RCTs.
  • OBJECTIVES: To summarise the data from RCTs testing the addition of RT to BCS for treatment of DCIS to determine the balance between the benefits and harms.
  • SEARCH STRATEGY: We searched the Cochrane Breast Cancer Group Specialised Register (January 2008), Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2008, Issue 1), MEDLINE (February 2008), and EMBASE (February 2008).
  • Three trials compared the addition of RT to BCS.
  • One trial was a two by two factorial design comparing the use of RT and tamoxifen, each separately or together, in which participants were randomised in at least one arm.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2009;(3):CD000563 [19588320.001]
  • (PMID = 19160183.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Number-of-references] 24
  •  go-up   go-down


45. Torija MJ, Mateo E, Guillamón JM, Mas A: Identification and quantification of acetic acid bacteria in wine and vinegar by TaqMan-MGB probes. Food Microbiol; 2010 Apr;27(2):257-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A Real-Time PCR (RT-PCR) assay was developed using TaqMan minor groove binder (MGB) probes for the specific detection and quantification of five acetic acid bacteria (AAB) species (Acetobacter pasteurianus, Acetobacter aceti, Gluconacetobacter hansenii, Gluconacetobacter europaeus and Gluconobacter oxydans) in wine and vinegar.
  • The RT-PCR assay used in this study is a reliable, specific and fast method for quantifying these five AAB species in wine and vinegar.

  • Hazardous Substances Data Bank. ACETIC ACID .
  • SILVA. SILVA SSU Database .
  • StrainInfo. culture/stock collections - online strain list (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20141944.001).
  • [ISSN] 1095-9998
  • [Journal-full-title] Food microbiology
  • [ISO-abbreviation] Food Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Probes; Q40Q9N063P / Acetic Acid
  •  go-up   go-down


46. Broeks A, Braaf LM, Huseinovic A, Schmidt MK, Russell NS, van Leeuwen FE, Hogervorst FB, Van 't Veer LJ: The spectrum of ATM missense variants and their contribution to contralateral breast cancer. Breast Cancer Res Treat; 2008 Jan;107(2):243-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have determined the spectrum and frequency of ATM missense variants in 443 breast cancer patients diagnosed before age 50, including 247 patients who subsequently developed CBC.
  • We have found that carriers of an ATM missense mutation, who were treated with radiotherapy for the first breast tumour, developed their second tumour on average in a 92-month interval compared to a 136-month mean interval for those CBC patients who neither received RT nor carried a germline variant, (p = 0.029).
  • However, the combination of RT and (certain) ATM missense variants seems to accelerate tumour development.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Cell Cycle Proteins / genetics. DNA-Binding Proteins / genetics. Mutation, Missense. Protein-Serine-Threonine Kinases / genetics. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2352-7 [16461462.001]
  • [Cites] Nat Genet. 2006 Aug;38(8):873-5 [16832357.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Jan;42(1):1-9 [15390180.001]
  • [Cites] N Engl J Med. 1992 Mar 19;326(12):781-5 [1538720.001]
  • [Cites] Natl Cancer Inst Monogr. 1985 Dec;68:99-112 [4088315.001]
  • [Cites] Nature. 1975 Dec 4;258(5534):427-9 [1196376.001]
  • [Cites] DNA Repair (Amst). 2004 Aug-Sep;3(8-9):1197-205 [15279808.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Jun;40(2):109-19 [15101044.001]
  • [Cites] Breast Cancer Res Treat. 2004 Jan;83(1):91-3 [14997059.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8717-25 [14695186.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Aug;12(8):733-8 [12917204.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3325-33 [12810666.001]
  • [Cites] Blood. 2002 Jul 15;100(2):603-9 [12091354.001]
  • [Cites] J Natl Cancer Inst. 2002 Feb 6;94(3):205-15 [11830610.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):925-30 [11805335.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5710-3 [11479203.001]
  • [Cites] Am J Hum Genet. 2001 Aug;69(2):396-412 [11443540.001]
  • [Cites] Am J Hum Genet. 2000 Feb;66(2):494-500 [10677309.001]
  • [Cites] Mol Genet Metab. 1999 Dec;68(4):419-23 [10607471.001]
  • [Cites] Mol Carcinog. 1999 Nov;26(3):143-9 [10559788.001]
  • [Cites] Hum Mutat. 2006 Nov;27(11):1122-8 [16958054.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 1;97(11):813-22 [15928302.001]
  • (PMID = 17393301.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ PMC2137941
  •  go-up   go-down


47. Cai Y, Shen XZ, Zhou CH, Wang JY: Abnormal expression of Smurf2 during the process of rat liver fibrosis. Chin J Dig Dis; 2006;7(4):237-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thereafter, a semi-quantitative RT-PCR, Western blot analysis and immunohistochemistry test were performed for determining Smurf2, Smad2 and SnoN at week 1, 2, 4 and 8 of establishing the liver fibrosis model.
  • RESULTS: Smurf2, FGG, PTAFR, CYP2D6, among others, increased in the fibrosis liver and a semi-quantitative RT-PCR confirmed the reliability of the cDNA microarray analysis.

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17054587.001).
  • [ISSN] 1443-9611
  • [Journal-full-title] Chinese journal of digestive diseases
  • [ISO-abbreviation] Chin J Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins; 0 / Smad2 Protein; 0 / SnoN protein, rat; 0 / Transcription Factors; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


48. Coe H, Bedard K, Groenendyk J, Jung J, Michalak M: Endoplasmic reticulum stress in the absence of calnexin. Cell Stress Chaperones; 2008 Dec;13(4):497-507
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we used beta-galactosidase reporter gene knock-in and reverse transcriptase polymerase chain reaction (RT-PCR) to investigate activation of the calnexin gene during embryonic development.
  • In contrast, non-stimulated calnexin-deficient cells showed increased activation of IRE1, as measured by RT-PCR and luciferase reporter gene analysis of splicing of Xbp1 mRNA and activation of the BiP promoter.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 2000 Aug 21;150(4):731-40 [10952999.001]
  • [Cites] Trends Biochem Sci. 2007 Oct;32(10):469-76 [17920280.001]
  • [Cites] Nat Genet. 2001 Jul;28(3):241-9 [11431694.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):9852-7 [12119418.001]
  • [Cites] Mol Cell Biol. 2002 Nov;22(21):7398-404 [12370287.001]
  • [Cites] J Biol Chem. 2002 Dec 27;277(52):50776-9 [12377773.001]
  • [Cites] Dev Cell. 2003 Feb;4(2):265-71 [12586069.001]
  • [Cites] J Biol Chem. 2004 Jun 18;279(25):25935-8 [15070890.001]
  • [Cites] J Biol Chem. 1991 Apr 15;266(11):7155-65 [2016321.001]
  • [Cites] EMBO J. 1995 Jun 1;14(11):2580-8 [7781611.001]
  • [Cites] J Biol Chem. 1995 Oct 27;270(43):25960-7 [7592786.001]
  • [Cites] EMBO J. 1996 Jun 17;15(12):2961-8 [8670797.001]
  • [Cites] J Biol Chem. 1998 Dec 11;273(50):33741-9 [9837962.001]
  • [Cites] J Cell Biol. 1999 Mar 8;144(5):857-68 [10085286.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2798-801 [10383134.001]
  • [Cites] Methods. 2005 Apr;35(4):395-416 [15804613.001]
  • [Cites] Nat Cell Biol. 2005 Aug;7(8):766-72 [16056268.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Dec 16;338(2):1018-30 [16256074.001]
  • [Cites] Neuron. 2006 Jan 19;49(2):229-41 [16423697.001]
  • [Cites] J Cell Sci. 2006 Feb 15;119(Pt 4):615-23 [16467570.001]
  • [Cites] J Biol Chem. 2006 Jul 7;281(27):18691-706 [16644724.001]
  • [Cites] PLoS Biol. 2006 Nov;4(11):e374 [17090218.001]
  • [Cites] Physiol Rev. 2007 Oct;87(4):1377-408 [17928587.001]
  • [Cites] Nature. 2001 Mar 8;410(6825):174-9 [11242070.001]
  • (PMID = 18528784.001).
  • [ISSN] 1355-8145
  • [Journal-full-title] Cell stress & chaperones
  • [ISO-abbreviation] Cell Stress Chaperones
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Heat-Shock Proteins; 0 / Molecular Chaperones; 0 / RNA, Messenger; 0 / Transcription Factors; 0 / molecular chaperone GRP78; 0 / regulatory factor X transcription factors; 139873-08-8 / Calnexin; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  • [Other-IDs] NLM/ PMC2673926
  •  go-up   go-down


49. Longyant S, Sithigorngul P, Chaivisuthangkura P, Rukpratanporn S, Sithigorngul W, Menasveta P: Differences in susceptibility of palaemonid shrimp species to yellow head virus (YHV) infection. Dis Aquat Organ; 2005 Apr 6;64(1):5-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some of each species were artificially infected with yellow head virus (YHV) by injection and then monitored by RT-PCR and by immunohistochemistry using monoclonal antibodies specific to 116 kDa, 64 kDa, and 20 kDa proteins of YHV.
  • Using immunohistochemistry and RT-PCR, a small proportion of M. lanchesteri showed very mild YHV infections at Day 3 but no infections at Days 10 and 30.
  • The evidence suggested that M. sintangense, P. styliferus and P. serrifer are susceptible to YHV and carry it for some time.
  • [MeSH-minor] Animals. Antibodies, Monoclonal. Aquaculture / methods. DNA Primers. Immunohistochemistry. Reverse Transcriptase Polymerase Chain Reaction. Thailand. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15900682.001).
  • [ISSN] 0177-5103
  • [Journal-full-title] Diseases of aquatic organisms
  • [ISO-abbreviation] Dis. Aquat. Org.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / DNA Primers
  •  go-up   go-down


50. Sacheck JM, Hyatt JP, Raffaello A, Jagoe RT, Roy RR, Edgerton VR, Lecker SH, Goldberg AL: Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases. FASEB J; 2007 Jan;21(1):140-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases.
  • To determine whether this transcriptional program also functions during atrophy resulting from loss of contractile activity and whether atrogene expression correlates with the rate of muscle weight loss, we used cDNA microarrays and RT-polymerase chain reaction to analyze changes in mRNA from rat gastrocnemius during disuse atrophy induced by denervation or spinal cord isolation.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17116744.001).
  • [ISSN] 1530-6860
  • [Journal-full-title] FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • [ISO-abbreviation] FASEB J.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / R01 AR055255-02; United States / NIAMS NIH HHS / AR / F32 AR048517; United States / NIAMS NIH HHS / AR / R01 AR055255; United States / NINDS NIH HHS / NS / NS16333; United States / NIDDK NIH HHS / DK / DK6230701
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


51. Yin GL, Yang JS, Cao JX, Yang WJ: Molecular cloning and characterization of FGLamide allatostatin gene from the prawn, Macrobrachium rosenbergii. Peptides; 2006 Jun;27(6):1241-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we used a combination of a semi-nested polymerase chain reaction (PCR) and screening of a central nervous system cDNA library of Macrobrachium rosenbergii to isolate and sequence a cDNA clone (2885 bp) encoding a 701 amino acid FGLamide allatostatin precursor polypeptide.
  • Reverse transcription-polymerase chain reaction (RT-PCR) analysis demonstrated that the gene was expressed in the brain, gut, thoracic and abdominal ganglia, but not in the heart, muscle, ovary, gill, or hepatopancreas.
  • Furthermore, developmentally-dependent expression of the gene was observed in the brain and thoracic ganglia of the prawn by using semi-quantitative RT-PCR analysis.
  • [MeSH-minor] Amino Acid Sequence. Animals. Base Sequence. Central Nervous System / metabolism. Cloning, Molecular. Crustacea. Female. Insects. Male. Molecular Sequence Data. Nucleic Acid Hybridization. Reverse Transcriptase Polymerase Chain Reaction. Tissue Distribution

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16376458.001).
  • [ISSN] 0196-9781
  • [Journal-full-title] Peptides
  • [ISO-abbreviation] Peptides
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neuropeptides; 0 / Peptides; 110119-33-0 / allatostatin
  •  go-up   go-down


52. Xiao L, Wei YZ, Xia F, Liu SW: [Construction of the fusion gene of Hsp65 of Mycobacterium tuberculosis and EGFP and preparation of dendritic cell vaccine against tuberculosis]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Jan;21(1):13-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The recombinant plasmid pEGHsp65 was subsequently transfected into Hela cells, and the transfection rate was determined under confocal laser scanning fluorescence microscope at different times.
  • RT-PCR was used to detect the expression of Hsp65 mRNA in Hela cells.
  • Expression of Hsp65 mRNA was detected in Hela cells by RT-PCR.

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Tuberculosis.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15629074.001).
  • [ISSN] 1007-8738
  • [Journal-full-title] Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  • [ISO-abbreviation] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Bacterial Vaccines; 0 / Chaperonin 60; 0 / DNA, Recombinant; 0 / enhanced green fluorescent protein; 0 / heat-shock protein 65, Mycobacterium; 147336-22-9 / Green Fluorescent Proteins; EC 3.1.21.- / DNA Restriction Enzymes; EC 3.6.1.- / Chaperonins
  •  go-up   go-down


53. Welzel G, Fleckenstein K, Mai SK, Hermann B, Kraus-Tiefenbacher U, Wenz F: Acute neurocognitive impairment during cranial radiation therapy in patients with intracranial tumors. Strahlenther Onkol; 2008 Dec;184(12):647-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute neurocognitive impairment during cranial radiation therapy in patients with intracranial tumors.
  • BACKGROUND AND PURPOSE: The objective of the current study was to evaluate the acute effects of cranial radiation therapy (CNS-RT) using different radiation doses (0, 1.8, 2, 3, >or=20 Gy) on cognitive function with special emphasis on memory.
  • We assessed patients with and without intracranial tumors to distinguish between direct and indirect radiation effects on brain tissue.
  • MATERIALS AND METHODS: Eighty-two patients were evaluated with neuropsychological testing before and acutely after radiotherapy (RT).
  • Sixty-four patients received RT to the brain (55 with, 9 without intracranial tumor).
  • Eighteen patients treated with RT to the breast served as controls.
  • RESULTS: Patients with intracranial tumor demonstrated attention (19-38th percentile) and verbal memory scores (34-46th percentile) below the population average at baseline.
  • The average Verbal Memory score was significantly different between patients with intracranial tumor and controls both at baseline (38th vs. 58th percentile) and after irradiation (27th vs. 52th percentile).
  • Radiation dose-related deficits were seen for working memory performance in patients with intracranial tumor.
  • Patients with intracranial tumor show a deterioration of almost all memory functions with a dose-dependent impairment in working memory.
  • Patients with preexisting peritumoral brain edema show the strongest deterioration.
  • [MeSH-major] Attention / radiation effects. Brain / radiation effects. Brain Neoplasms / radiotherapy. Cognition / radiation effects. Cranial Irradiation / adverse effects. Memory / radiation effects. Radiotherapy / adverse effects
  • [MeSH-minor] Adult. Aged. Brain Edema / complications. Data Interpretation, Statistical. Female. Humans. Male. Middle Aged. Neuropsychological Tests. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Memory.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Life Sci. 1996;58(17):1475-83 [8622574.001]
  • [Cites] Neuropsychiatry Neuropsychol Behav Neurol. 2000 Apr;13(2):101-11 [10780628.001]
  • [Cites] Strahlenther Onkol. 2005 Mar;181(3):141-56 [15756518.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):157-65 [14701778.001]
  • [Cites] Brain Res Mol Brain Res. 1999 Jul 23;71(1):61-8 [10407187.001]
  • [Cites] Magn Reson Imaging. 1997;15(4):423-32 [9223043.001]
  • [Cites] Strahlenther Onkol. 2002 May;178(5):252-8 [12082684.001]
  • [Cites] Neuroscience. 2003;119(3):635-42 [12809684.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3470-6 [11481352.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1497-501 [11121654.001]
  • [Cites] Neurology. 2005 Jan 25;64(2):335-7 [15668434.001]
  • [Cites] Strahlenther Onkol. 2007 Aug;183(8):440-6 [17680224.001]
  • [Cites] Stereotact Funct Neurosurg. 2001;76(1):36-46 [12007277.001]
  • [Cites] Strahlenther Onkol. 2000 Dec;176(12):573-81 [11140152.001]
  • [Cites] Arch Clin Neuropsychol. 2004 Jun;19(4):497-506 [15163451.001]
  • [Cites] Exp Neurol. 2004 Aug;188(2):316-30 [15246832.001]
  • [Cites] Nat Neurosci. 2000 Apr;3(4):313-4 [10725918.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23 (18):4127-36 [15961760.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4021-7 [12874001.001]
  • [Cites] Radiother Oncol. 2003 Nov;69(2):177-82 [14643955.001]
  • [Cites] J Psychopharmacol. 2002 Mar;16(1):65-71 [11949774.001]
  • [Cites] Psychoneuroendocrinology. 2005 Apr;30(3):225-42 [15511597.001]
  • [Cites] Strahlenther Onkol. 2007 Oct;183(10):576-80 [17896090.001]
  • [Cites] J Neurosci. 1994 Apr;14(4):2047-53 [8198631.001]
  • [Cites] J Neurooncol. 1995;25(3):227-38 [8592173.001]
  • [Cites] Invest Radiol. 2003 Sep;38(9):539-49 [12960523.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jul 1;44(4):891-4 [10386647.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 15;34(5):1037-44 [8600086.001]
  • [Cites] AJNR Am J Neuroradiol. 1994 Apr;15(4):625-32 [8010261.001]
  • [Cites] Radiat Res. 2004 Jul;162(1):39-47 [15222778.001]
  • [Cites] Radiat Res. 2004 Jan;161(1):17-27 [14680400.001]
  • [Cites] Strahlenther Onkol. 2003 Jul;179(7):441-51 [12835880.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):995-9 [9869221.001]
  • [Cites] J Clin Oncol. 1995 Sep;13(9):2263-71 [7666084.001]
  • [Cites] Radiother Oncol. 1996 Oct;41(1):55-9 [8961368.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):706-13 [14966095.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):101-11 [15093905.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Dec 24;325(4):1223-35 [15555557.001]
  • [Cites] Nat Med. 2002 Sep;8(9):955-62 [12161748.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1430-7 [12459366.001]
  • [Cites] Strahlenther Onkol. 2007 May;183(5):248-55 [17497096.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2070-5 [9215274.001]
  • [Cites] Strahlenther Onkol. 2006 Jul;182(7):382-8 [16826356.001]
  • (PMID = 19107345.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


54. Allen TL, Jolley SJ, Cooley VJ, Winn RT, Harrison JD, Price RR, Rich JC: The epidemiology of illness and injury at the alpine venues during the Salt Lake City 2002 Winter Olympic Games. J Emerg Med; 2006 Feb;30(2):197-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Over the 19 days of the Olympiad, a total of 410,160 spectators and 3,961 competitive athletes attended the three venues.

  • MedlinePlus Health Information. consumer health - Emergency Medical Services.
  • MedlinePlus Health Information. consumer health - Wounds and Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16567258.001).
  • [ISSN] 0736-4679
  • [Journal-full-title] The Journal of emergency medicine
  • [ISO-abbreviation] J Emerg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Laskar S, Muckaden MA, Bahl G, de S, Nair R, Gupta S, Bakshi A, Prabhash K, Maru D, Gujral S, Parikh P, Shrivastava SK, Dinshaw KA: Primary non-Hodgkin's lymphoma of the nasopharynx: prognostic factors and outcome of 113 Indian patients. Leuk Lymphoma; 2006 Oct;47(10):2132-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphoma of the nasopharynx: prognostic factors and outcome of 113 Indian patients.
  • This single institutional study evaluated the prognostic factors and treatment outcome of 113 Indian patients with primary nasopharyngeal non-Hodgkin's lymphoma.
  • Treatment comprised of a combination of chemotherapy (CTh) and radiotherapy (RT) in the majority of the patients (76%).
  • Multivariate analysis showed that; age > 30 years [hazard ratio (HR) = 6.59, 95% confidence interval (CI) = 2.59 - 16.7, P < 0.0001], WHO performance score > or = 2 (HR = 2.34, 95% CI = 1.01 - 5.46, P = 0.050), T-cell lymphomas (HR = 2.81, 95% CI = 1.14 - 6.96, P < 0.001) and the presence of B symptoms (HR = 3.65, 95% CI = 1.77 - 7.53, P = 0.025), had a negative influence on survival.
  • Patients treated with a combination of CTh and RT had a significantly better outcome than those treated with CTh alone (OS: 69%vs. 31%, P < 0.00001).
  • The CR (P = 0.01), DFS (P = 0.01) and OS (P = 0.03) rates were significantly better for patients receiving a RT dose of > or =4500 cGy.
  • HR in the subgroup that received a RT dose of <4500 cGy was 2.51 (95% CI = 1.04 - 6.06).
  • These results suggest that combined modality treatment, comprising of CTh and RT (with an RT dose of > or =4500 cGy), results in satisfactory outcome in patients with this rare neoplasm.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Combined Modality Therapy / methods. Female. Humans. India. Male. Middle Aged. Prognosis. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17071487.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


56. Heinzelmann F, Engelhard M, Ottinger H, Bamberg M, Weinmann M: Nodal follicular lymphoma: the role of radiotherapy for stages I and II. Strahlenther Onkol; 2010 Apr;186(4):191-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To clarify the role of external-beam radiotherapy (RT) in patients with stage I and II nodal follicular lymphoma (FL).
  • RESULTS: In patients with stage I and II nodal FL, RT alone with different irradiation techniques (involved-field [IFI]/extended-field [EFI]/total nodal [TNI]/total lymphoid irradiation [TLI]) produces excellent local disease control (approximately 95%) resulting in disease-free survival and overall survival (OS) rates of 37-94% and 40-93% at 5-15 years, respectively.
  • Additional chemotherapy mostly failed to improve treatment results achieved with RT alone.
  • To further improve the curative potential of RT in early-stage FL, novel combined approaches (e.g., RT + immunotherapy with rituximab) are under investigation.
  • [MeSH-minor] Disease-Free Survival. Humans. Lymphatic Irradiation / methods. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Risk Factors. Whole-Body Irradiation / methods

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Strahlenther Onkol. 2008 Mar;184(3):145-9 [18330510.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):188-93 [16111588.001]
  • [Cites] Semin Radiat Oncol. 2007 Jul;17(3):198-205 [17591567.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4143-9 [16896003.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1417-23 [15494430.001]
  • [Cites] Radiother Oncol. 1984 Dec;2(4):301-12 [6395212.001]
  • [Cites] Cancer. 1995 May 1;75(9):2361-7 [7712449.001]
  • [Cites] Med Oncol. 1994;11(1):19-25 [7921924.001]
  • [Cites] J Clin Oncol. 1993 Feb;11(2):233-8 [8426199.001]
  • [Cites] Cancer. 1979 Sep;44(3):831-8 [383273.001]
  • [Cites] Cancer. 1983 Dec 15;52(12):2300-7 [6416664.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1398-403 [12663733.001]
  • [Cites] Strahlenther Onkol. 2008 Jan;184(1):8-14 [18188517.001]
  • [Cites] Cancer. 1983 Jul 1;52(1):1-7 [6406037.001]
  • [Cites] Strahlenther Onkol. 2008 Aug;184(8):400-5 [18956516.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):748-54 [14529780.001]
  • [Cites] Radiother Oncol. 1995 Sep;36(3):167-71 [8532901.001]
  • [Cites] Strahlenther Onkol. 1992 Feb;168(2):66-72 [1542848.001]
  • [Cites] Radiology. 1973 Sep;108(3):675-84 [4579361.001]
  • [Cites] Strahlenther Onkol. 2003 Oct;179(10):694-701 [14566478.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):387-90 [9457825.001]
  • [Cites] Clin Cancer Res. 1997 Feb;3(2):215-9 [9815675.001]
  • [Cites] Cancer. 1986 Oct 15;58(8):1596-602 [3756784.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1219-27 [11728680.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]
  • [Cites] Strahlenther Onkol. 2007 Dec;183 Spec No 2:16-8 [18167000.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] J Clin Oncol. 2003 Jun 1;21(11):2115-22 [12775737.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):928-34 [16243446.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1986-92 [17420513.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1980 Feb;6(2):125-34 [6993438.001]
  • [Cites] Cancer. 1976 Jun;37(6):2806-12 [949700.001]
  • [Cites] Br J Cancer. 1994 Jun;69(6):1088-93 [8198975.001]
  • [Cites] Blood. 2008 Dec 15;112(13):4824-31 [18799723.001]
  • [Cites] N Engl J Med. 2005 Feb 3;352(5):441-9 [15689582.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 Apr;10(4):489-97 [6725039.001]
  • [Cites] Cancer. 1997 Dec 15;80(12):2273-84 [9404705.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):643-51 [11849785.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1282-90 [8648385.001]
  • [Cites] J Clin Oncol. 1984 Jul;2(7):841-8 [6376723.001]
  • [Cites] Eur J Cancer. 1996 Mar;32A(3):470-9 [8814695.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jun 1;44(3):563-8 [10348285.001]
  • [Cites] Br J Haematol. 2007 May;137(3):216-20 [17408460.001]
  • [Cites] Blood. 2002 May 15;99(10):3806-12 [11986240.001]
  • [Cites] Radiother Oncol. 1985 Nov;4(3):211-23 [3909240.001]
  • [Cites] Pathology. 2005 Dec;37(6):409-19 [16373224.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2955-60 [9531606.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Strahlenther Onkol. 2008 Aug;184(8):406-10 [18956517.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2780-95 [9704731.001]
  • [Cites] Strahlenther Onkol. 2007 Aug;183(8):417-23; discussion 424-5 [17680220.001]
  • [Cites] Cancer. 1993 Apr 1;71(7):2342-50 [8453557.001]
  • [Cites] Strahlenther Onkol. 2009 May;185(5):288-95 [19440667.001]
  • [Cites] Strahlenther Onkol. 2003 Dec;179(12):840-6 [14652673.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):3-15 [11163492.001]
  • (PMID = 20354662.001).
  • [ISSN] 1439-099X
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 60
  •  go-up   go-down


57. Choi GB, Shin JH, Song HY, Lee YS, Cho YK, Bae JI, Kim JH, Jeong YH, Park MH: Fluoroscopically guided balloon dilation for patients with esophageal stricture after radiation treatment. J Vasc Interv Radiol; 2005 Dec;16(12):1705-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate the safety and clinical effectiveness of fluoroscopically guided balloon dilation in patients with esophageal stricture after radiation therapy (RT).
  • MATERIALS AND METHODS: From April 1993 through December 2004, fluoroscopically guided balloon dilation was performed in 15 patients with esophageal strictures secondary to previous RT.
  • Technical success, clinical success, recurrence of dysphagia, primary and secondary patency rates, and complications related to the procedure were retrospectively evaluated.
  • Dysphagia recurred 2-128 days (mean, 67.2 d) after the first balloon dilation in six of the 13 patients (46%), who underwent further balloon dilation and/or stent placement.
  • The primary and secondary patency rates at 1, 3, and 6 months were 86%, 68%, and 47% and 100%, 92%, and 62%, respectively.
  • CONCLUSION: Fluoroscopically guided balloon dilation for esophageal stricture after RT can be safe and effective.

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16371539.001).
  • [ISSN] 1051-0443
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Bessong PO, Obi CL, Andréola ML, Rojas LB, Pouységu L, Igumbor E, Meyer JJ, Quideau S, Litvak S: Evaluation of selected South African medicinal plants for inhibitory properties against human immunodeficiency virus type 1 reverse transcriptase and integrase. J Ethnopharmacol; 2005 May 13;99(1):83-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Seventeen aqueous and methanol extracts from nine South African medicinal plants, ethnobotanically selected, were screened for inhibitory properties against HIV-1 reverse transcriptase (RT).
  • The strongest inhibition against the RNA-dependent-DNA polymerase (RDDP) activity of RT was observed with the methanol extract of the stem-bark of Peltophorum africanum Sond. (Fabaceae) (IC(50) 3.5 microg/ml), while the methanol extract of the roots of Combretum molle R.Br. ex G.
  • The gallotannin inhibited the RDDP and RNase H functions of RT with IC(50) values of 6.0 and 5.0 microM, respectively, and abolished the 3'-end processing activity of IN at 100 microM.
  • Catechin showed no effect on RT but had a moderate activity on HIV-1 IN.
  • [MeSH-minor] Cell Survival / drug effects. Combretum / chemistry. DNA, Viral / drug effects. Ethanol. Humans. Medicine, African Traditional. Plant Extracts / chemistry. Plant Extracts / pharmacology. Solvents. South Africa. Tumor Cells, Cultured. Water

  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETHANOL .
  • Hazardous Substances Data Bank. Water .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15848024.001).
  • [ISSN] 0378-8741
  • [Journal-full-title] Journal of ethnopharmacology
  • [ISO-abbreviation] J Ethnopharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / DNA, Viral; 0 / HIV Integrase Inhibitors; 0 / Plant Extracts; 0 / Reverse Transcriptase Inhibitors; 0 / Solvents; 059QF0KO0R / Water; 3K9958V90M / Ethanol; EC 2.7.7.- / HIV Integrase; EC 2.7.7.49 / HIV Reverse Transcriptase
  •  go-up   go-down


59. Schweighofer B, Testori J, Sturtzel C, Sattler S, Mayer H, Wagner O, Bilban M, Hofer E: The VEGF-induced transcriptional response comprises gene clusters at the crossroad of angiogenesis and inflammation. Thromb Haemost; 2009 Sep;102(3):544-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As shown by real-time RT-PCR for selected genes, VEGF-induction was mostly mediated by VEGF receptor-2 and the capacity of VEGF-A to induce genes in common with IL-1 largely depended on activation of the calcineurin/NFAT pathway, since cyclosporin A inhibited this induction.
  • [MeSH-major] Gene Expression Regulation. Inflammation. Neovascularization, Pathologic. Transcription, Genetic. Vascular Endothelial Growth Factor A / metabolism
  • [MeSH-minor] Calcineurin / metabolism. Cyclosporine / metabolism. Endothelial Cells / cytology. Humans. Interleukin-1 / metabolism. Models, Genetic. Multigene Family. Oligonucleotide Array Sequence Analysis. Reverse Transcriptase Polymerase Chain Reaction. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1997 Jan 9;385(6612):172-6 [8990122.001]
  • [Cites] J Biochem Mol Biol. 2006 Sep 30;39(5):469-78 [17002866.001]
  • [Cites] Thromb Haemost. 2007 Mar;97(3):355-63 [17334501.001]
  • [Cites] Thromb Haemost. 2007 Mar;97(3):364-9 [17334502.001]
  • [Cites] Thromb Haemost. 2007 Jun;97(6):988-97 [17549302.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10595-600 [17567755.001]
  • [Cites] Nat Rev Immunol. 2007 Sep;7(9):678-89 [17717539.001]
  • [Cites] Neuroscience. 2007 Sep 7;148(3):633-43 [17692471.001]
  • [Cites] Nat Rev Immunol. 2007 Oct;7(10):803-15 [17893694.001]
  • [Cites] Oncogene. 2008 May 8;27(21):2989-98 [18059339.001]
  • [Cites] J Surg Res. 2008 Oct;149(2):171-6 [18694572.001]
  • [Cites] Nat Rev Cancer. 2008 Dec;8(12):942-56 [19029957.001]
  • [Cites] Science. 1997 Apr 11;276(5310):248-50 [9092472.001]
  • [Cites] FASEB J. 1997 May;11(6):457-65 [9194526.001]
  • [Cites] Neuron. 1997 Dec;19(6):1261-9 [9427249.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9349-54 [9689083.001]
  • [Cites] Annu Rev Immunol. 1993;11:767-804 [8476577.001]
  • [Cites] J Biol Chem. 1994 Oct 28;269(43):26988-95 [7929439.001]
  • [Cites] J Clin Invest. 1996 Jun 1;97(11):2672-9 [8647962.001]
  • [Cites] Clin Immunol Immunopathol. 1996 Sep;80(3 Pt 2):S40-5 [8811062.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Jul;7(7):505-16 [16829981.001]
  • [Cites] J Neurochem. 2006 Jun;97(5):1403-11 [16638018.001]
  • [Cites] Development. 1998 Nov;125(22):4565-74 [9778514.001]
  • [Cites] J Biol Chem. 2004 Nov 26;279(48):50537-54 [15448146.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1076-81 [15644447.001]
  • [Cites] Nat Immunol. 2005 May;6(5):472-80 [15834410.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):159-78 [15863032.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4521-32 [15958638.001]
  • [Cites] Nature. 2005 Jul 14;436(7048):193-200 [16015319.001]
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):659-67 [16256984.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 May;7(5):359-71 [16633338.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7163-9 [11156426.001]
  • [Cites] FASEB J. 2001 Jan;15(1):230-242 [11149911.001]
  • [Cites] J Biol Chem. 2001 Jul 27;276(30):28451-8 [11337506.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4454-61 [12393577.001]
  • [Cites] Nucleic Acids Res. 2003 Mar 15;31(6):1753-64 [12626717.001]
  • [Cites] Nat Med. 2003 Jun;9(6):653-60 [12778163.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Nat Med. 2003 Jun;9(6):677-84 [12778166.001]
  • [Cites] J Cell Biol. 2003 Jun 23;161(6):1163-77 [12810700.001]
  • [Cites] Nat Med. 2003 Jul;9(7):936-43 [12796773.001]
  • [Cites] Cancer Sci. 2003 Sep;94(9):751-6 [12967471.001]
  • [Cites] J Cell Sci. 2004 Mar 15;117(Pt 8):1319-28 [15020672.001]
  • [Cites] Blood. 2004 Jul 1;104(1):149-58 [15016650.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Jul;24(7):1192-8 [15130917.001]
  • [Cites] FASEB J. 2004 Aug;18(11):1264-6 [15180964.001]
  • [Cites] Endocr Rev. 2004 Aug;25(4):581-611 [15294883.001]
  • (PMID = 19718476.001).
  • [ISSN] 0340-6245
  • [Journal-full-title] Thrombosis and haemostasis
  • [ISO-abbreviation] Thromb. Haemost.
  • [Language] eng
  • [Grant] Austria / Austrian Science Fund FWF / / S 9403
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Interleukin-1; 0 / Vascular Endothelial Growth Factor A; 83HN0GTJ6D / Cyclosporine; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; EC 3.1.3.16 / Calcineurin
  • [Other-IDs] NLM/ PMC2886966; NLM/ UKMS30254
  •  go-up   go-down


60. Petch LA, Hoffman IF, Jere CS, Kazembe PN, Martinson FE, Chilongozi D, Fiscus SA, Cohen MS: Genotypic analysis of the protease and reverse transcriptase of HIV type 1 subtype C isolates from antiretroviral drug-naive adults in Malawi. AIDS Res Hum Retroviruses; 2005 Sep;21(9):799-805
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The protease (PR) and reverse transcriptase (RT) regions of HIV-1 isolates from 21 antiretroviral (ARV)-naive Malawian adults were sequenced and analyzed to determine the prevalence of drug resistance-associated mutations in this population.
  • No major mutations associated with resistance to PR inhibitors (PIs), nucleoside RT inhibitors (NRTIs), or nonnucleoside RT inhibitors (NNRTIs) were found.
  • In contrast, accessory mutations were found in the protease region at positions 10, 20, 36, 63, 77, and 93, and in the RT region at positions 118, 211, and 214.
  • [MeSH-minor] Adult. Amino Acid Sequence. Consensus Sequence. Drug Resistance, Viral / genetics. Humans. Malawi. Molecular Sequence Data. Mutation. Phylogeny. Sequence Alignment

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • Stanford HIV Drug Resistance Database. gene/protein/disease-specific - Stanford HIV Drug Resistance Database .
  • LANL HIV Databases. LANL HIV Databases .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16218804.001).
  • [ISSN] 0889-2229
  • [Journal-full-title] AIDS research and human retroviruses
  • [ISO-abbreviation] AIDS Res. Hum. Retroviruses
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AY860456/ AY860457/ AY860458/ AY860459/ AY860460/ AY860461/ AY860462/ AY860463/ AY860464/ AY860465/ AY860466/ AY860467/ AY860468/ AY860469/ AY860470/ AY860471/ AY860472/ AY860473/ AY860474/ AY860475/ AY860476/ AY860477/ AY860478/ AY860479/ AY860480/ AY860481/ AY860482/ AY860483/ AY860484/ AY860485/ AY860486/ AY860487/ AY860488/ AY860489/ AY860490/ AY860491/ AY860492/ AY860493/ AY860494/ AY860495/ AY860496/ AY860497
  • [Grant] United States / NIAID NIH HHS / AI / 5 U01 AI048005-04; United States / FIC NIH HHS / TW / D43 TW01039-05S1; United States / NIAID NIH HHS / AI / P30 AI50410
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.7.49 / HIV Reverse Transcriptase; EC 3.4.23.- / HIV Protease
  •  go-up   go-down


61. Shivers S, Jakub J, Pendas S, Reintgen D: Molecular staging for patients with malignant melanoma. Expert Rev Anticancer Ther; 2007 Nov;7(11):1665-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular staging for patients with malignant melanoma.
  • With newer reverse transcriptase-PCR (RT-PCR)-based assays, sensitivities reported are as high as identifying one cancer cell in a background of a million normal cells.
  • Although this sensitivity is 100-times what the human eye can differentiate under the microscope, the new challenge becomes determining the relevance of this low-volume disease in the regional basin, in particular, the sentinel lymph node (SLN).
  • Patients with melanomas greater than 0.75 mm in tumor thickness participated in a research study that examined their SLNs with routine histology, immunhistochemical staining and a RT-PCR assay based on the tyrosinase probe.
  • A total of 311 patients were involved in the study and patients whose SLN were negative from all three assays for metastatic disease had a good survival, with a 92% disease-free survival (DFS) and a 97% overall survival (OS) regardless of the tumor thickness or the ulceration status of the primary melanoma.
  • Patients upstaged with the RT-PCR assay had a significantly decreased DFS and OS compared with patients who were SLN negative.
  • Patients who had enough tumor burden in the SLN that allowed their metastatic disease to be identified with routine histology had a 48% recurrence rate at 5 years.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Clinical Trials as Topic. Humans. Lymphatic Metastasis. Neoplasm Staging. Nerve Growth Factors / analysis. Prognosis. RNA, Neoplasm / genetics. Radionuclide Imaging. Reverse Transcriptase Polymerase Chain Reaction. S100 Calcium Binding Protein beta Subunit. S100 Proteins / analysis. Sensitivity and Specificity. Sentinel Lymph Node Biopsy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18020932.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nerve Growth Factors; 0 / RNA, Neoplasm; 0 / S100 Calcium Binding Protein beta Subunit; 0 / S100 Proteins
  •  go-up   go-down


62. Ikema K, Matsumoto K, Inomata Y, Komohara Y, Miyajima S, Takeya M, Tanihara H: Induction of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs correlates with outcome of acute experimental pseudomonal keratitis. Exp Eye Res; 2006 Dec;83(6):1396-404
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pseudomonal keratitis was induced in New Zealand white rabbits, and macroscopic and microscopic examinations were performed at appropriate time points (3, 9, 12, 18, 24, 72 h).
  • Expressions and sources of MMP-2, 9, and TIMP-1, 2 were determined using immunohistochemistry, gelatin zymography, ELISA, and RT-PCR.
  • MMP-2 was constitutively expressed in keratocytes, and its expression was not apparently enhanced after pseudomonal infection as evidenced by zymography, immunostaining, and RT-PCR.
  • Although TIMP-2 was constitutively expressed as seen by immunostaining and RT-PCR, its concentration was below detection limits during the experiments.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16968651.001).
  • [ISSN] 0014-4835
  • [Journal-full-title] Experimental eye research
  • [ISO-abbreviation] Exp. Eye Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Tissue Inhibitor of Metalloproteinase-1; 0 / Tissue Inhibitor of Metalloproteinases; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.- / Matrix Metalloproteinases; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


63. Dzialowski I, Hill MD, Coutts SB, Demchuk AM, Kent DM, Wunderlich O, von Kummer R: Extent of early ischemic changes on computed tomography (CT) before thrombolysis: prognostic value of the Alberta Stroke Program Early CT Score in ECASS II. Stroke; 2006 Apr;37(4):973-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Alberta Stroke Program Early CT Score (ASPECTS) semiquantitatively assesses EICs within the middle cerebral artery territory using a10-point grading system.
  • METHODS: Data from the European-Australian Acute Stroke Study (ECASS) II study were used in which 800 patients were randomized to recombinant tissue plasminogen activator (rt-PA) or placebo within 6 hours of symptom onset.
  • We performed a multivariable logistic regression analysis and assessed for an interaction between rt-PA treatment and baseline ASPECTS score.
  • CONCLUSIONS: In ECASS II, the effect of rt-PA on functional outcome is not influenced by baseline ASPECTS.
  • [MeSH-major] Brain Ischemia / drug therapy. Brain Ischemia / radiography. Fibrinolytic Agents / therapeutic use. Tissue Plasminogen Activator / therapeutic use. Tomography, X-Ray Computed
  • [MeSH-minor] Aged. Cerebral Hemorrhage / chemically induced. Cerebral Hemorrhage / epidemiology. Female. Humans. Incidence. Injections, Intravenous. Male. Middle Aged. Middle Cerebral Artery / radiography. Predictive Value of Tests. Prognosis. Randomized Controlled Trials as Topic. Recombinant Proteins / administration & dosage. Recombinant Proteins / therapeutic use. Time Factors

  • Genetic Alliance. consumer health - Ischemic stroke.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16497977.001).
  • [ISSN] 1524-4628
  • [Journal-full-title] Stroke; a journal of cerebral circulation
  • [ISO-abbreviation] Stroke
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fibrinolytic Agents; 0 / Recombinant Proteins; EC 3.4.21.68 / Tissue Plasminogen Activator
  •  go-up   go-down


64. Schlueter SR, Carnes DL, Cochran DL: In vitro effects of enamel matrix derivative on microvascular cells. J Periodontol; 2007 Jan;78(1):141-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Periodontal regeneration requires a coordinated series of events that includes not only the recruitment of periodontal ligament (PDL)-specific cells, but vascular cells as well.
  • The mechanisms of action of enamel matrix derivative (EMD) are poorly understood, and its effects on vascular cells are unknown.
  • Effects of EMD on PDL expression of vascular endothelial cell (VEGF) types (A, B, C, and D) and isoforms were determined using reverse transcription-polymerase chain reaction (RT-PCR).
  • RT-PCR results indicated that PDL cells expressed VEGF-A, -B, and -C and multiple isoforms of VEGF-A, including VEGF(121), VEGF(165), and VEGF(189), whether or not EMD was present in the culture media.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17199551.001).
  • [ISSN] 0022-3492
  • [Journal-full-title] Journal of periodontology
  • [ISO-abbreviation] J. Periodontol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dental Enamel Proteins; 0 / Growth Substances; 0 / enamel matrix proteins
  •  go-up   go-down


65. Lei RC, Jian XC, Qin ZQ: [Change of the expression level of Th1 and Th2 cytokines around the xenogeneic cancellous bone scaffold after transplantation: an experiment in rabbits]. Zhonghua Zheng Xing Wai Ke Za Zhi; 2007 Nov;23(6):507-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histological investigation and the expression of Th1 (such as IL-2, IFN-gamma) and Th2 (such as IL-4, IL-10) mRNA were measured by HE, RT-PCR respectively in 1,2,4,8,12 week postoperation.
  • RT-PCR revealed: The mRNA expression level of Th1 cytokines such as IL-2, IFN-gamma was high in 1 week and began to fall since 2 week.

  • MedlinePlus Health Information. consumer health - Bone Grafts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18269028.001).
  • [ISSN] 1009-4598
  • [Journal-full-title] Zhonghua zheng xing wai ke za zhi = Zhonghua zhengxing waike zazhi = Chinese journal of plastic surgery
  • [ISO-abbreviation] Zhonghua Zheng Xing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cytokines; 0 / RNA, Messenger
  •  go-up   go-down


66. Yu L, Ma H, Yang SJ: [Expression of HSP70 in human umbilical vein endothelial cells induced by Hantavirus]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Jan;21(1):9-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The expression of HSP70 was detected by immunocytochemical staining, in situ nucleic acid hybridization and RT-PCR.
  • RT-PCR showed that the level of HSP70 mRNA increased rapidly and kept at a high level in comparison with the normal control (P<0.05).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15629073.001).
  • [ISSN] 1007-8738
  • [Journal-full-title] Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  • [ISO-abbreviation] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / HSP70 Heat-Shock Proteins; 0 / RNA, Messenger
  •  go-up   go-down


67. Delviks-Frankenberry KA, Nikolenko GN, Barr R, Pathak VK: Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3'-azido-3'-deoxythymidine resistance. J Virol; 2007 Jul;81(13):6837-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3'-azido-3'-deoxythymidine resistance.
  • We recently observed that mutations in the human immunodeficiency type 1 (HIV-1) reverse transcriptase (RT) connection domain significantly increase 3'-azido-3'-deoxythymidine (AZT) resistance up to 536 times over wild-type (WT) RT in the presence of thymidine analog resistance mutations (TAMs).
  • These mutations also decreased RT template switching, suggesting that they altered the balance between nucleotide excision and template RNA degradation, which in turn increased AZT resistance.
  • To test the hypothesis that connection domain mutations enhanced AZT resistance by influencing the RNase H primer grip, we determined the effects of alanine substitutions in RNase H primer grip residues on nucleoside RT inhibitor resistance in the context of a WT, TAM-containing, or K65R-containing polymerase domain.
  • Ten of the 11 RNase H primer grip mutations increased AZT resistance 20 to 243 times above WT levels in the context of a TAM-containing polymerase domain.
  • These results demonstrate that mutations in the RNase H primer grip region can significantly enhance AZT resistance and support the hypothesis that mutations in the connection and RNase H domains can increase resistance by altering the RNase H primer grip region, changing interactions between RT and the template-primer complex and/or shifting the balance between the polymerase and RNase H activities.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ZIDOVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochemistry. 2002 Apr 16;41(15):4856-65 [11939780.001]
  • [Cites] J Biol Chem. 2002 Jan 11;277(2):1370-4 [11684697.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):10090-5 [12119402.001]
  • [Cites] J Virol. 2003 Aug;77(15):8548-54 [12857924.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Sep;36(9):1687-705 [15183338.001]
  • [Cites] J Virol. 2004 Aug;78(16):8761-70 [15280484.001]
  • [Cites] Nature. 1970 Jun 27;226(5252):1209-11 [4316300.001]
  • [Cites] Nature. 1970 Jun 27;226(5252):1211-3 [4316301.001]
  • [Cites] Cell. 1979 Sep;18(1):93-100 [509527.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):6320-4 [7687065.001]
  • [Cites] J Virol. 1994 Sep;68(9):5721-9 [7520094.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9564-8 [7937806.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 1998;58:339-93 [9308371.001]
  • [Cites] Biopolymers. 1997;44(2):125-38 [9354757.001]
  • [Cites] J Mol Biol. 1998 Dec 11;284(4):1095-111 [9837729.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):2093-8 [15684061.001]
  • [Cites] J Antimicrob Chemother. 2005 Jun;55(6):817-20 [15845781.001]
  • [Cites] Curr Med Chem. 2006;13(3):313-24 [16475939.001]
  • [Cites] Virology. 2006 May 10;348(2):378-88 [16473384.001]
  • [Cites] Top HIV Med. 2006 Aug-Sep;14(3):125-30 [16946457.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):317-22 [17179211.001]
  • [Cites] Science. 1998 Nov 27;282(5394):1669-75 [9831551.001]
  • [Cites] J Virol. 2000 Aug;74(15):7171-8 [10888659.001]
  • [Cites] EMBO J. 2001 Mar 15;20(6):1449-61 [11250910.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12209-14 [11593039.001]
  • [Cites] J Virol. 2002 Jan;76(1):88-95 [11739674.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9515-20 [12093908.001]
  • (PMID = 17428874.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA primers; 0 / Reverse Transcriptase Inhibitors; 4B9XT59T7S / Zidovudine; 63231-63-0 / RNA; EC 2.7.7.49 / HIV Reverse Transcriptase; EC 3.1.26.4 / Ribonuclease H
  • [Other-IDs] NLM/ PMC1933283
  •  go-up   go-down


68. Ertan Y, Sezak M, Turhan T, Kantar M, Erşahin Y, Mutluer S, Vergin C, Oniz H, Akalin T: Atypical teratoid/rhabdoid tumor of the central nervous system: clinicopathologic and immunohistochemical features of four cases. Childs Nerv Syst; 2009 Jun;25(6):707-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical teratoid/rhabdoid tumor of the central nervous system: clinicopathologic and immunohistochemical features of four cases.
  • BACKGROUND: Atypical teratoid/rhabdoid tumor (AT/RT) is a rare aggressive infantile neoplasm of uncertain origin.
  • This study was performed to assess the clinicopathologic and immunohistochemical features of four AT/RT cases.
  • Tumors were located in the cerebellum (two cases), frontoparietal lobe (one case), and third ventricle (one case).
  • Histopathologically, the tumors were composed of rhabdoid cells and undifferentiated small cells mixed with epithelial or mesenchymal components.
  • However, one of the tumors was composed predominantly of a mesenchymal component mimicking a sarcoma.
  • All of the patients died within a mean of 14 months due to tumor progression despite the chemotherapy.
  • In conclusion, AT/RTs are aggressive tumors.
  • [MeSH-major] Brain Neoplasms / pathology. Rhabdoid Tumor / pathology. Teratoma / pathology
  • [MeSH-minor] Actins / analysis. Brain / pathology. Brain Chemistry. Child. Child, Preschool. Chromosomal Proteins, Non-Histone / analysis. DNA-Binding Proteins / analysis. Desmin / analysis. Diagnosis, Differential. Female. Glial Fibrillary Acidic Protein / analysis. Humans. Immunohistochemistry. Infant. Keratins / analysis. Male. Mucin-1 / analysis. S100 Proteins / analysis. SMARCB1 Protein. Synaptophysin / analysis. Transcription Factors / analysis. Vimentin / analysis

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Childs Nerv Syst. 2009 Nov;25(11):1387; author reply 1389 [19636570.001]
  • [Cites] Pediatr Neurosurg. 2006;42(3):187-92 [16636624.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Mod Pathol. 2005 Jul;18(7):951-8 [15761491.001]
  • [Cites] J Neurooncol. 1995;24(1):21-8 [8523069.001]
  • [Cites] J Neurooncol. 2005 Dec;75(3):309-13 [16195799.001]
  • [Cites] J Neurooncol. 2008 Jul;88(3):321-30 [18369529.001]
  • [Cites] Acta Neuropathol. 1992;83(4):445-8 [1575023.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Jun-Jul;24(5):337-42 [12142780.001]
  • [Cites] J Neurooncol. 1998 Dec;40(3):265-75 [10066100.001]
  • [Cites] J Neurosurg. 1996 Jul;85(1):56-65 [8683283.001]
  • [Cites] Neuropathology. 2002 Dec;22(4):252-60 [12564764.001]
  • [Cites] Neurol Med Chir (Tokyo). 1999 Jul;39(7):510-7; discussion 517-8 [10437379.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):644-50 [15105654.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1485-91 [15489652.001]
  • [Cites] Acta Neuropathol. 2000 May;99(5):482-8 [10805090.001]
  • [Cites] Am J Surg Pathol. 1998 Sep;22(9):1083-92 [9737241.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 May;64(5):391-7 [15892296.001]
  • [Cites] Ultrastruct Pathol. 1997 Jul-Aug;21(4):369-78 [9206002.001]
  • [Cites] Childs Nerv Syst. 2008 Jan;24(1):143-7 [17968559.001]
  • (PMID = 19212771.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Actins; 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / Desmin; 0 / Glial Fibrillary Acidic Protein; 0 / Mucin-1; 0 / S100 Proteins; 0 / SMARCB1 Protein; 0 / SMARCB1 protein, human; 0 / Synaptophysin; 0 / Transcription Factors; 0 / Vimentin; 68238-35-7 / Keratins
  •  go-up   go-down


69. Manini T, Marko M, VanArnam T, Cook S, Fernhall B, Burke J, Ploutz-Snyder L: Efficacy of resistance and task-specific exercise in older adults who modify tasks of everyday life. J Gerontol A Biol Sci Med Sci; 2007 Jun;62(6):616-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of resistance and task-specific exercise in older adults who modify tasks of everyday life.
  • BACKGROUND: The purpose of this study was to determine the efficacy of 10 weeks of resistance (RT), functional (FT), or functional plus resistance (FRT) training in older adults who modify tasks of everyday life and are at risk for subsequent disability.
  • The primary outcome of the study was the number of task modifications and timed performance on eight tasks of daily life.
  • Secondary outcomes included knee and elbow strength (extension and flexion), body composition, self-reported physical function, single-leg balance time, walking speed, and time to vacuum a carpet.
  • The RT group performed progressive intensity training, and the FT group performed task-specific exercises 2 days per week.
  • All three training groups reduced the need to modify tasks of everyday life (RT: 21%, FRT: 26%, and FT: 28%) and improved self-rated function and time to vacuum a carpet.
  • Individuals who performed FT either 1 or 2 days per week also reduced their timed performance (RT: 2.5% [p = 0.48], FRT: 18.5%, and FT: 23%).
  • Strength gains were primarily found in groups that performed RT either 1 or 2 days per week (RT and FRT).
  • [MeSH-minor] Aged. Body Composition / physiology. Elbow Joint / physiology. Female. Follow-Up Studies. Gait / physiology. Humans. Isometric Contraction / physiology. Knee Joint / physiology. Male. Muscle Strength / physiology. Postural Balance / physiology. Risk Factors. Task Performance and Analysis. Time Factors. Walking / physiology. Weight Lifting

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17595417.001).
  • [ISSN] 1079-5006
  • [Journal-full-title] The journals of gerontology. Series A, Biological sciences and medical sciences
  • [ISO-abbreviation] J. Gerontol. A Biol. Sci. Med. Sci.
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / P30 AG028740
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


70. Rades D, Schild SE: Treatment recommendations for the various subgroups of neurocytomas. J Neurooncol; 2006 May;77(3):305-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study was performed to determine the best available treatment for typical and atypical neurocytomas (MIB-1 labeling index >3%, atypical histology) in various age groups ( <or=18 years, >18 years).
  • Patients were treated with complete resection alone (CTR), CTR plus radiotherapy (CTR + RT), incomplete resection alone (ITR), or ITR plus radiotherapy (ITR + RT).
  • Three hundred and fifty-one patients had typical, 87 atypical lesions.
  • Typical lesions were associated with better local control and survival than atypical lesions (P < 0.001).
  • After CTR, outcome was not significantly improved by RT.
  • After ITR, RT improved survival in typical lesions (P = 0.03) and atypical lesions (P = 0.05), not in children (P = 0.16).
  • Doses >54 Gy appeared beneficial after ITR of atypical lesions.
  • In children, <or=50 Gy and >50 Gy were comparable.CTR does not require post-operative RT.
  • Following ITR, RT improves outcome.
  • Atypical lesions require 56-60 Gy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1999 Jul 3;354(9172):34-9 [10406363.001]
  • [Cites] Neuro Oncol. 2005 Jan;7(1):77-83 [15701284.001]
  • [Cites] J Neurosurg. 1994 Aug;81(2):288-93 [8027814.001]
  • [Cites] Neurology. 2004 Mar 23;62(6):987-9 [15037708.001]
  • [Cites] Neurosurg Rev. 1997;20(1):39-43 [9085286.001]
  • [Cites] Am J Surg Pathol. 2001 Oct;25(10):1252-60 [11688459.001]
  • [Cites] J Neurosurg. 1999 Apr;90(2 Suppl):247-51 [10199257.001]
  • [Cites] Acta Neuropathol. 1997 Nov;94(5):425-35 [9386774.001]
  • [Cites] Neurosurg Rev. 2001 Mar;24(1):48-52 [11339470.001]
  • [Cites] Cancer. 2004 Dec 1;101(11):2629-32 [15494975.001]
  • [Cites] Pathol Res Pract. 2003;199(7):463-8 [14521262.001]
  • [Cites] J Neurosurg. 1997 Mar;86(3):547-52 [9046315.001]
  • [Cites] Brain Tumor Pathol. 2001;18(1):29-36 [11517971.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):297-306 [8293189.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):814-7 [14770439.001]
  • [Cites] J Clin Neurosci. 2000 Nov;7(6):548-52 [11029240.001]
  • [Cites] Ann Pathol. 2000 Dec;20(6):558-63 [11148351.001]
  • [Cites] Cancer. 2000 Sep 1;89(5):1111-20 [10964342.001]
  • [Cites] Acta Neuropathol. 1982;56(2):151-6 [7064664.001]
  • [Cites] Acta Radiol. 1993 Sep;34(5):520-6 [8369193.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Jun-Jul;18(6):1175-8 [9194446.001]
  • [Cites] Surg Neurol. 1998 Feb;49(2):197-204 [9457271.001]
  • (PMID = 16575540.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 22
  •  go-up   go-down


71. Taal W, Brandsma D, de Bruin HG, Bromberg JE, Swaak-Kragten AT, Smitt PA, van Es CA, van den Bent MJ: Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer; 2008 Jul 15;113(2):405-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide.
  • BACKGROUND: Radiotherapy (RT) plus concomitant and adjuvant temozolomide (TMZ) is now the standard of care for patients with newly diagnosed glioblastoma.
  • The occurrence of pseudo-progression directly after RT is a recognized phenomenon, but to the authors' knowledge its incidence after combined RT/TMZ is unknown.
  • The occurrence of early pseudo-progression was retrospectively assessed in a cohort of malignant glioma patients treated with RT/TMZ.
  • METHODS: The pre-RT and post-RT brain scans from patients treated with RT/TMZ for a malignant glioma were reviewed.
  • Scans were made before the start of RT, 4 weeks after the end of RT, and every 3 months thereafter.
  • In 36 patients (42%) the first follow-up scan 4 weeks after the end of RT indicated disease progression.
  • Six of 18 patients with pseudo-progression and 12 of the 18 patients with real tumor progression developed new clinical signs and symptoms during RT or in the first 4 weeks thereafter.
  • CONCLUSIONS: Up to 50% of malignant glioma patients treated with RT/TMZ and progression immediately after RT develop pseudo-progression.
  • The current study data support the idea to continue TMZ in the case of progressive lesions immediately after RT/TMZ.
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Combined Modality Therapy. Disease Progression. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Retrospective Studies. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • (PMID = 18484594.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


72. Tamm K, Rõõm M, Salumets A, Metsis M: Genes targeted by the estrogen and progesterone receptors in the human endometrial cell lines HEC1A and RL95-2. Reprod Biol Endocrinol; 2009;7:150
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Expression analysis by reverse transcriptase (RT)-PCR was used to further investigate hormone dependent mRNA expression regulation of a subset of genes.
  • RT-PCR analysis of 20 genes demonstrated transcriptional changes after estradiol or progesterone treatment of the cell lines.
  • CONCLUSIONS: Combined results from ChIP-qPCR and RT-PCR analysis showed different patterns of steroid hormone receptor occupancy at target genes, corresponding to activation or suppression of gene expression after hormone treatment of HEC1A and RL95-2 cell lines.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2001 Mar 9;104(5):719-30 [11257226.001]
  • [Cites] Endocrinology. 2009 Aug;150(8):3871-6 [19372202.001]
  • [Cites] Endocrinology. 2002 Jun;143(6):2119-38 [12021176.001]
  • [Cites] Mol Hum Reprod. 2002 Sep;8(9):871-9 [12200466.001]
  • [Cites] Mol Endocrinol. 2002 Oct;16(10):2338-48 [12351698.001]
  • [Cites] Mol Hum Reprod. 2002 Nov;8(11):1014-22 [12397214.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Jan;4(1):46-56 [12511868.001]
  • [Cites] Mol Endocrinol. 2003 Feb;17(2):203-8 [12554748.001]
  • [Cites] Curr Opin Drug Discov Devel. 2003 Sep;6(5):692-701 [14579519.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Mar;89(3):1429-42 [15001645.001]
  • [Cites] Nat Rev Immunol. 2004 May;4(5):381-6 [15122203.001]
  • [Cites] Am J Obstet Gynecol. 1972 Dec 15;114(8):1012-9 [4673779.001]
  • [Cites] In Vitro. 1983 Mar;19(3 Pt 1):147-58 [6339371.001]
  • [Cites] J Biol Chem. 1990 Jul 25;265(21):12163-7 [2373686.001]
  • [Cites] BMJ. 1990 Jun 2;300(6737):1428-31 [2379001.001]
  • [Cites] Placenta. 1993 Jan-Feb;14(1):13-24 [8456086.001]
  • [Cites] J Cell Physiol. 1993 Apr;155(1):185-96 [8468365.001]
  • [Cites] Mol Endocrinol. 1993 Oct;7(10):1244-55 [8264658.001]
  • [Cites] Mol Endocrinol. 1993 Oct;7(10):1256-65 [8123133.001]
  • [Cites] Mol Cell Biol. 1994 Dec;14(12):8356-64 [7969170.001]
  • [Cites] Eur J Cell Biol. 1996 Jul;70(3):221-32 [8832206.001]
  • [Cites] FEBS Lett. 1997 Jun 23;410(1):87-90 [9247129.001]
  • [Cites] J Biol Chem. 1997 Aug 8;272(32):19858-62 [9242648.001]
  • [Cites] Nucleic Acids Res. 1997 Sep 1;25(17):3389-402 [9254694.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Dec;82(12):4258-65 [9398750.001]
  • [Cites] Curr Opin Cell Biol. 1998 Jun;10(3):373-83 [9640539.001]
  • [Cites] Mol Hum Reprod. 1999 Jun;5(6):559-64 [10341004.001]
  • [Cites] Cell Mol Life Sci. 2005 Jan;62(2):239-50 [15666095.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1812-8 [15613410.001]
  • [Cites] Hum Reprod. 2005 Aug;20(8):2104-17 [15878921.001]
  • [Cites] Hum Reprod Update. 2005 Nov-Dec;11(6):613-30 [16006437.001]
  • [Cites] Mol Endocrinol. 2006 Aug;20(8):1707-14 [16396959.001]
  • [Cites] Endocrinology. 2006 Sep;147(9):4079-92 [16794005.001]
  • [Cites] Nat Genet. 2006 Oct;38(10):1204-9 [16951680.001]
  • [Cites] J Mol Med (Berl). 2006 Nov;84(11):901-10 [16972087.001]
  • [Cites] Fertil Steril. 2007 Jun;87(6):1419-27 [17383649.001]
  • [Cites] PLoS Genet. 2007 Jun;3(6):e87 [17542648.001]
  • [Cites] Nucl Recept Signal. 2008;6:e005 [18301785.001]
  • [Cites] Endocrinology. 2009 Mar;150(3):1466-72 [18974268.001]
  • [Cites] Reprod Biol Endocrinol. 2009;7:14 [19220894.001]
  • [Cites] Cell Mol Life Sci. 2009 Aug;66(15):2405-26 [19333551.001]
  • [Cites] Genome Res. 2002 Apr;12(4):656-64 [11932250.001]
  • (PMID = 20034404.001).
  • [ISSN] 1477-7827
  • [Journal-full-title] Reproductive biology and endocrinology : RB&E
  • [ISO-abbreviation] Reprod. Biol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chromatin; 0 / RNA, Messenger; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  • [Other-IDs] NLM/ PMC2805670
  •  go-up   go-down


73. Reinbold JB, Coetzee JF, Hollis LC, Nickell JS, Riegel C, Olson KC, Ganta RR: The efficacy of three chlortetracycline regimens in the treatment of persistent Anaplasma marginale infection. Vet Microbiol; 2010 Sep 28;145(1-2):69-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic carrier status was established in 21 steers with a Virginia isolate of Anaplasma marginale and confirmed by cELISA and an A. marginale-specific RT-PCR.
  • Blood samples were collected semi-weekly for determining plasma drug concentration by ultrahigh performance liquid chromatography-mass spectrometry/mass spectrometry method and assessment of disease status by both cELISA and RT-PCR.
  • A negative RT-PCR assay result was confirmed in all CTC-treated groups within 49 days of treatment; however, cELISA required an additional 49 to 88 days before similar results.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20346598.001).
  • [ISSN] 1873-2542
  • [Journal-full-title] Veterinary microbiology
  • [ISO-abbreviation] Vet. Microbiol.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI070908; United States / NIAID NIH HHS / AI / AI070908
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] WCK1KIQ23Q / Chlortetracycline
  •  go-up   go-down


74. Nikonova AA, Uspenskaia ES, Lobodanov SA, Oksanich AS, Gorbalenia AE, Claas EC, Foshina EP, Kaira AN, Zverev VV, Faĭzuloev EB: [Use of multiplex PCR method with real-time detection for differential diagnosis of respiratory viral infections]. Zh Mikrobiol Epidemiol Immunobiol; 2009 Jan-Feb;(1):67-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Use of multiplex PCR method with real-time detection for differential diagnosis of respiratory viral infections].
  • Multiplex real-time polymerase chain reaction test-system with fluorescent detection (RT-PCR) for simultaneous identification of main agents of acute respiratory viral infections: influenza A (IAV) and B viruses (IBV), parainfluenza viruses types 1, 2, 3, 4 (PIV 1 - 4), adenoviruses (ADV), respiratory syncitial virus (RSV), rhinoviruses (RV) and enteroviruses (EV), in presence internal positive control (IPC) represented by vaccine strain of rubella virus RA 27/3.
  • Using multiplex RT-PCR method, respiratory viruses were detected in 116 out of 226 clinical samples (nasal swabs) obtained from patients with symptoms of acute respiratory infection: in 68 (58.6%) samples--IBV; in 21 (18.1%)--IAV; in 12 (10.3%) --RV; in 6 (5.2%)--PIV 2; in 4--(3.4%) ADV; in 3 (2.6%)--RSV; in 2 (1.7%)--EV; in 2 (1.7%)--PIV 4; in 1 (0.9%)--PIV 3; in 1 (0.9%)--PIV 1.
  • At the same time samples were tested for the presence of 12 respiratory viruses--IAV, IBV, PIV 1 - 4, RSV, RV, metapneumoviruses, and coronaviruses NL63, 229E and OC43--in the presence of IPC represented by equine arteritis virus using analogous PCR test-system provided by medical center of Leiden university.
  • Results of tests for detection of IAV, IBV, RSV, PIV 1 - 4, and RV, analyzed by both systems, agreed in 94%.
  • Multiplex format of RT-PCR performing significantly reduces time and cost of the test, which make it suitable and effective instrument of epidemiological studies.

  • MedlinePlus Health Information. consumer health - Viral Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19338239.001).
  • [ISSN] 0372-9311
  • [Journal-full-title] Zhurnal mikrobiologii, epidemiologii, i immunobiologii
  • [ISO-abbreviation] Zh. Mikrobiol. Epidemiol. Immunobiol.
  • [Language] rus
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Viral; 0 / RNA, Viral
  •  go-up   go-down


75. Wang T, Zhang J: Synthesis of 2-acylfurans from 3-(1-alkynyl)-2-alken-1-ones via the oxidation of gold-carbene intermediates by H2O2. Dalton Trans; 2010 May 14;39(18):4270-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An efficient approach to 2,4,5-trisubstituted 2-acylfurans is described: treating 3-(1-alkynyl)-2-alken-1-ones with AuCl3 in DCM at rt in the presence of H2O2 afforded good yields of 2-acylfurans.

  • Hazardous Substances Data Bank. Furan .
  • Hazardous Substances Data Bank. METHANE .
  • Hazardous Substances Data Bank. GOLD, ELEMENTAL .
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20379602.001).
  • [ISSN] 1477-9234
  • [Journal-full-title] Dalton transactions (Cambridge, England : 2003)
  • [ISO-abbreviation] Dalton Trans
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alkenes; 0 / Furans; 2465-56-7 / carbene; 7440-57-5 / Gold; BBX060AN9V / Hydrogen Peroxide; OP0UW79H66 / Methane; UC0XV6A8N9 / furan
  •  go-up   go-down


76. Kocher M, Frommolt P, Borberg SK, Rühl U, Steingräber M, Niewald M, Staar S, Stuschke M, Becker G, Fischedick AR, Herfarth K, Grauthoff H, Müller RP: Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma. Strahlenther Onkol; 2008 Nov;184(11):572-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: From February 2002 to July 2004, n = 65 patients from 11 German centers with macroscopic complete tumor resection were randomized to receive either postoperative radiotherapy alone (RT, n = 35) or postoperative radiotherapy with simultaneous temozolomide (RT + TMZ, n = 30).
  • Patients were stratified according to age (< or =/>50 years) and WHO performance score (0-1 vs. 2).
  • RT consisted of 60 Gy in 30 fractions.
  • In the RT + TMZ arm, oral TMZ was administered daily at a dose of 75 mg/m(2) including weekends (40-42 doses).
  • Adjuvant treatment was not given, but in both arms, patients with recurrent tumors and in good condition (WHO 0-2) were scheduled for salvage chemotherapy with TMZ.
  • In total, 62/65 patients were evaluable.
  • Stratification variables were well balanced (< or = 50 years 26% vs. 20%, WHO 0-1 91% vs. 100%).
  • In the RT (RT + TMZ) arm, 76% (62%) of the progressing patients received salvage chemotherapy with TMZ, 36% (50%) had a second resection.
  • There was a time-constant trend for increased general quality of life (EORTC questionnaire QLQ C30) and brain-specific quality of life (EORTC questionnaire B20) in the combined arm.
  • Lymphopenia G3-4 was more frequent (33 vs. 6%) in the RT + TMZ arm.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Dacarbazine / analogs & derivatives. Glioblastoma / drug therapy. Glioblastoma / radiotherapy

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19016015.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


77. Li X, Chai T, Wang Z, Song C, Cao H, Liu J, Zhang X, Wang W, Yao M, Miao Z: Occurrence and transmission of Newcastle disease virus aerosol originating from infected chickens under experimental conditions. Vet Microbiol; 2009 May 12;136(3-4):226-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to better understand airborne transmission of Newcastle disease, a model system was established and two trials were conducted.
  • The antibody response to infection was assessed by the hemagglutination inhibition (HI) test and viral shedding was detected by RT-PCR and Dot-ELISA.
  • NDV aerosol was initially detectable by RT-PCR and cell culture at day 2 or 3 post-inoculation (dpi).
  • [MeSH-minor] Aerosols. Animals. Antibodies, Viral / blood. Chick Embryo. Enzyme-Linked Immunosorbent Assay / veterinary. Hemagglutination Inhibition Tests / veterinary. RNA, Viral / chemistry. RNA, Viral / genetics. Reverse Transcriptase Polymerase Chain Reaction / veterinary. Specific Pathogen-Free Organisms. Virus Shedding

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19091492.001).
  • [ISSN] 0378-1135
  • [Journal-full-title] Veterinary microbiology
  • [ISO-abbreviation] Vet. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Aerosols; 0 / Antibodies, Viral; 0 / RNA, Viral
  •  go-up   go-down


78. Roquebert B, Marcelin AG: The involvement of HIV-1 RNAse H in resistance to nucleoside analogues. J Antimicrob Chemother; 2008 May;61(5):973-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The involvement of HIV-1 RNAse H in resistance to nucleoside analogues.
  • Some recent studies have underlined the role of the entire reverse transcriptase (RT) and in particular its carboxy-terminal domain from amino acid 427 to amino acid 560 [the ribonuclease H (RNAse H) domain] in resistance to nucleoside RT inhibitors (NRTIs).
  • In vitro, the mutations H539N and D549N decreased the frequency of RT template-switching and, thereby, increased the time for excision of incorporated NRTIs, and thus enhanced NRTI resistance.
  • It has been confirmed in vivo that mutations at position 558 were statistically associated with a number of thymidine analogue mutations in a study including 144 HIV-1 patients, suggesting that it could be an accessory mutation that could reinforce NRTI resistance.
  • This article highlights evidence that mutations in RNAse H can enhance NRTI resistance, suggesting that phenotypic and genotypic analyses of clinical samples including the entire HIV-1 RT and in particular the RNAse H domain are now required to better characterize the in vivo role of the RNAse H mutations on susceptibility and response to NRTIs in HIV-1-infected patients.
  • [MeSH-major] Anti-HIV Agents / pharmacology. Drug Resistance, Multiple, Viral / genetics. HIV-1 / drug effects. HIV-1 / enzymology. Ribonuclease H / genetics. Ribonuclease H / metabolism

  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18325896.001).
  • [ISSN] 1460-2091
  • [Journal-full-title] The Journal of antimicrobial chemotherapy
  • [ISO-abbreviation] J. Antimicrob. Chemother.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents; EC 2.7.7.49 / RNA-Directed DNA Polymerase; EC 3.1.26.4 / Ribonuclease H
  • [Number-of-references] 19
  •  go-up   go-down


79. Youngpairoj AS, Masciotra S, Garrido C, Zahonero N, de Mendoza C, García-Lerma JG: HIV-1 drug resistance genotyping from dried blood spots stored for 1 year at 4 degrees C. J Antimicrob Chemother; 2008 Jun;61(6):1217-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-1 drug resistance genotyping from dried blood spots stored for 1 year at 4 degrees C.
  • BACKGROUND: Dried blood spots (DBSs) are an attractive alternative to plasma for HIV-1 drug resistance testing in resource-limited settings.
  • METHODS: A total of 40 DBSs were prepared from residual diagnostic specimens collected from HIV subtype B-infected persons and were stored with desiccant at 4 degrees C.
  • Total nucleic acids were extracted after 1 year using a modification of the Nuclisens assay.
  • Resistance testing was performed using the ViroSeq HIV-1 assay and an in-house nested RT-PCR method validated for HIV-1 subtype B that amplifies a smaller (1 kb) pol fragment.
  • Overall, resistance genotypes generated from the DBSs and plasma were highly concordant.
  • CONCLUSIONS: We show that drug resistance genotyping from DBSs stored at 4 degrees C with desiccant is highly efficient but requires the amplification of small pol fragments and the use of an in-house nested PCR protocol with quality-controlled reagents.
  • [MeSH-major] Blood / virology. Drug Resistance / genetics. HIV Infections / virology. HIV-1 / genetics. HIV-1 / isolation & purification. Microbial Sensitivity Tests / methods. Specimen Handling / methods
  • [MeSH-minor] Desiccation. Genotype. Humans. Nucleic Acids / isolation & purification. Refrigeration. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity. Time Factors


80. Pinto FL, Svensson H, Lindblad P: Webtag: a new web tool providing tags/anchors for RT-PCR experiments with prokaryotes. BMC Biotechnol; 2007;7:73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Webtag: a new web tool providing tags/anchors for RT-PCR experiments with prokaryotes.
  • RESULTS: The use of a relational database, in conjunction with a series of scripts written in PHP and Perl, allows the user to rapidly obtain tags that are:.
  • CONCLUSION: This new web tool allows scientists to easily and rapidly obtain suitable tags for RT-PCR experiments, and is available at http://www.egs.uu.se/software/webtag/.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2001 Jul;15(7):1033-7 [11455970.001]
  • [Cites] Biotechniques. 1996 Jun;20(6):1012-4, 1016, 1018-20 [8780872.001]
  • [Cites] J Biochem Mol Biol. 2002 Mar 31;35(2):248-50 [12297038.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1460-5 [9465037.001]
  • [Cites] BMC Biotechnol. 2006;6:31 [16820068.001]
  • [Cites] Biochemistry. 2004 Mar 30;43(12):3537-54 [15035624.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2004 Apr;23(4):289-99 [15015033.001]
  • [Cites] Nature. 1988 Jun 30;333(6176):858-60 [3290682.001]
  • [Cites] Gene. 1990 Jul 2;91(1):139-42 [1698167.001]
  • [Cites] J Mol Biol. 1990 Oct 5;215(3):403-10 [2231712.001]
  • [Cites] Biotechniques. 1991 Dec;11(6):760-3 [1725598.001]
  • [Cites] Leukemia. 1994 Feb;8(2):327-35 [7905944.001]
  • [Cites] Cytotechnology. 1993;12(1-3):289-314 [7509167.001]
  • [Cites] PCR Methods Appl. 1994 Oct;4(2):S83-91 [7580879.001]
  • [Cites] Biotechniques. 2001 Oct;31(4):776-8, 780, 782 [11680707.001]
  • (PMID = 17961214.001).
  • [ISSN] 1472-6750
  • [Journal-full-title] BMC biotechnology
  • [ISO-abbreviation] BMC Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Oligonucleotides
  • [Other-IDs] NLM/ PMC2147000
  •  go-up   go-down


81. Geenen MM, Bakker PJ, Kremer LC, Kastelein JJ, van Leeuwen FE: Increased prevalence of risk factors for cardiovascular disease in long-term survivors of acute lymphoblastic leukemia and Wilms tumor treated with radiotherapy. Pediatr Blood Cancer; 2010 Oct;55(4):690-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased prevalence of risk factors for cardiovascular disease in long-term survivors of acute lymphoblastic leukemia and Wilms tumor treated with radiotherapy.
  • We determined the prevalence of CRFs in long-term survivors of acute lymphoblastic leukemia (ALL) and Wilms tumor.
  • PROCEDURE: Adult survivors of ALL and Wilms tumor treated with radiotherapy and chemotherapy (RT + CT) or treated with chemotherapy alone (CT) were compared with sibling controls.
  • RESULTS: Seventy-nine ALL, 62 Wilms tumor survivors, and 69 control subjects (mean ages 24.5, 25.9, and 26 years, respectively) were enrolled.
  • Mean follow-up time since cancer treatment was 20.8 years.
  • In the Wilms RT + CT group significantly more survivors had hypertension (21.6% vs. 1.4%, P < 0.001) and renal insufficiency (8.1% vs. 0%, P = 0.016) compared to controls.
  • There were also more patients with multiple CRFs in the Wilms RT + CT group (16.2% vs. 2.9% in controls, P = 0.019).
  • Almost 15% of ALL RT + CT survivors had growth hormone deficiency.
  • Hypogonadism was seen in 18.9% of survivors in the Wilms RT + CT group.
  • CONCLUSIONS: Long-term survivors of ALL and Wilms tumor have unfavorable CRFs due to previous RT not CT.
  • [MeSH-major] Cardiovascular Diseases / etiology. Kidney Neoplasms / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Wilms Tumor / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Wiley-Liss, Inc.
  • (PMID = 20589650.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lipids
  •  go-up   go-down


82. Goodwin A, Parker S, Ghersi D, Wilcken N: Post-operative radiotherapy for ductal carcinoma in situ of the breast. Cochrane Database Syst Rev; 2009;(4):CD000563
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The addition of radiotherapy (RT) following breast conserving surgery (BCS) was first shown to reduce the risk of ipsilateral recurrence in the treatment of invasive breast cancer.
  • Randomised controlled trials (RCTs) have shown that RT can reduce the risk of recurrence, but assessment of potential long-term complications from addition of RT following BSC for DCIS has not been reported for women participating in RCTs.
  • OBJECTIVES: To summarise the data from RCTs testing the addition of RT to BCS for treatment of DCIS to determine the balance between the benefits and harms.
  • SEARCH STRATEGY: We searched the Cochrane Breast Cancer Group Specialised Register (January 2008), Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2008, Issue 1), MEDLINE (February 2008), and EMBASE (February 2008).
  • Three trials compared the addition of RT to BCS.
  • One trial was a two by two factorial design comparing the use of RT and tamoxifen, each separately or together, in which participants were randomised in at least one arm.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2013;11:CD000563 [24259251.001]
  • [UpdateOf] Cochrane Database Syst Rev. 2009;(3):CD000563 [19588320.001]
  • (PMID = 19821272.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Number-of-references] 24
  •  go-up   go-down


83. Arraj A, Bohatier J, Aumeran C, Bailly JL, Laveran H, Traoré O: An epidemiological study of enteric viruses in sewage with molecular characterization by RT-PCR and sequence analysis. J Water Health; 2008 Sep;6(3):351-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An epidemiological study of enteric viruses in sewage with molecular characterization by RT-PCR and sequence analysis.
  • The reverse transcriptase-polymerase chain reaction (RT-PCR) results were confirmed by sequencing, and comparative phylogenetic analysis was performed on the isolated strains.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19108555.001).
  • [ISSN] 1477-8920
  • [Journal-full-title] Journal of water and health
  • [ISO-abbreviation] J Water Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Sewage
  •  go-up   go-down


84. Arthur Woods H, Bonnecaze RT: Insect eggs at a transition between diffusion and reaction limitation: temperature, oxygen, and water. art.woods@mso.umt.edu. J Theor Biol; 2006 Dec 21;243(4):483-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We fit the model to previously published data on development time of eggs of a sphingid moth, Manduca sexta.
  • We test then this conclusion with independent data on development times of eggs distributed across a set of temperatures generated by a thermal gradient bar.

  • Hazardous Substances Data Bank. Water .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16930626.001).
  • [ISSN] 0022-5193
  • [Journal-full-title] Journal of theoretical biology
  • [ISO-abbreviation] J. Theor. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 059QF0KO0R / Water
  •  go-up   go-down


85. Cui HL, Qiao JT: Effect of lysophosphatidic acid on differentiation of embryonic neural stem cells into neuroglial cells in rats in vitro. Sheng Li Xue Bao; 2007 Dec 25;59(6):759-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RT-PCR assay was also used for analyzing the expression of LPA receptors in NSCs.
  • Exposure to LPA led to a dose-dependent increase of oligodendrocytes with the response peaked at 1.0 mumol/L, with an increased percentage of 32.6% (P<0.01) of total cells as compared to that of 8.5% in the vehicle group. (2) LPA showed no effect on the differentiation of NSCs into astrocytes. (3) RT-PCR assay showed that LPA(1) and LPA(3) receptors were strongly expressed while LPA(2) receptor expressed weakly in NSCs.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18157468.001).
  • [ISSN] 0371-0874
  • [Journal-full-title] Sheng li xue bao : [Acta physiologica Sinica]
  • [ISO-abbreviation] Sheng Li Xue Bao
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Lysophospholipids; 0 / Receptors, Lysophosphatidic Acid; 22002-87-5 / lysophosphatidic acid
  •  go-up   go-down


86. Ammerlaan AC, Ararou A, Houben MP, Baas F, Tijssen CC, Teepen JL, Wesseling P, Hulsebos TJ: Long-term survival and transmission of INI1-mutation via nonpenetrant males in a family with rhabdoid tumour predisposition syndrome. Br J Cancer; 2008 Jan 29;98(2):474-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival and transmission of INI1-mutation via nonpenetrant males in a family with rhabdoid tumour predisposition syndrome.
  • Rhabdoid tumour predisposition syndrome (RTPS) is a rare syndrome caused by inheritance of a mutated INI1 gene for which only two multigeneration families have been reported.
  • To further characterise the genotype and phenotype of RTPS, we present a third family in which at least three cousins developed an atypical teratoid/rhabdoid tumour (AT/RT) at a young age.
  • Biallelic inactivation of INI1 in the tumours, except for the meningioma, was confirmed by absence of nuclear INI1-protein staining.
  • The myoepithelioma of one of the patients carried an identical somatic rearrangement in the NF2 gene as the AT/RT, indicating that both tumours originated from a common precursor cell.
  • In conclusion, this study demonstrates for the first time transmission of a germline INI1-mutation in a RTPS family via nonpenetrant males, long-term survival of two members of this family with an AT/RT, and involvement of INI1 in the pathogenesis of myoepithelioma.
  • [MeSH-major] Chromosomal Proteins, Non-Histone / genetics. DNA-Binding Proteins / genetics. Family. Genetic Predisposition to Disease. Germ-Line Mutation. Inheritance Patterns. Penetrance. Rhabdoid Tumor / genetics. Transcription Factors / genetics
  • [MeSH-minor] Adolescent. Adult. Base Sequence. Child, Preschool. Chromosomes, Human, Pair 22. DNA Mutational Analysis. Female. Humans. Infant. Male. Microsatellite Repeats / genetics. Pedigree. Sex Characteristics. Survival Analysis. Syndrome. Time Factors

  • MedlinePlus Health Information. consumer health - Family Issues.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mutat. 1999;13(4):290-3 [10220142.001]
  • [Cites] Mol Cell. 1999 Feb;3(2):247-53 [10078207.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1491-9 [15735125.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 May;64(5):391-7 [15892296.001]
  • [Cites] J Neurooncol. 2005 Dec;75(3):279-85 [16195802.001]
  • [Cites] Neurosurg Focus. 2006;20(1):E11 [16459991.001]
  • [Cites] Neurosurg Focus. 2006;20(1):E8 [16459998.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Apr;28(4):241-8 [16679923.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 May;27(5):962-71 [16687525.001]
  • [Cites] Pediatr Blood Cancer. 2006 Sep;47(3):279-84 [16261613.001]
  • [Cites] Am J Surg Pathol. 2006 Nov;30(11):1462-8 [17063089.001]
  • [Cites] J Neurooncol. 2007 Jan;81(1):97-111 [16855864.001]
  • [Cites] Am J Hum Genet. 2007 Apr;80(4):805-10 [17357086.001]
  • [Cites] Am J Hum Genet. 2000 Apr;66(4):1403-6 [10739763.001]
  • [Cites] J Natl Cancer Inst. 2000 Apr 19;92(8):648-50 [10772683.001]
  • [Cites] Acta Neuropathol. 2001 May;101(5):479-82 [11484819.001]
  • [Cites] Acta Neuropathol. 2001 Jul;102(1):69-74 [11547953.001]
  • [Cites] J Pathol. 2002 Dec;198(4):487-94 [12434418.001]
  • [Cites] Neurology. 2003 Jun 24;60(12):1968-74 [12821741.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):127-33 [14526201.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Jun;40(2):133-9 [15101046.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):644-50 [15105654.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1994 Oct;57(10):1245-8 [7931388.001]
  • [Cites] Am J Hum Genet. 1995 Mar;56(3):608-15 [7887414.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Aug;13(4):272-7 [7547635.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1668-71 [8658145.001]
  • [Cites] Genes Dev. 1996 Sep 1;10(17):2117-30 [8804307.001]
  • [Cites] Trends Biochem Sci. 1998 Jun;23(6):198-9 [9644970.001]
  • [Cites] Hum Mol Genet. 1999 Dec;8(13):2359-68 [10556283.001]
  • [Cites] Br J Cancer. 1999 Dec;81(7):1150-4 [10584875.001]
  • [Cites] Nature. 1998 Jul 9;394(6689):203-6 [9671307.001]
  • [Cites] Am J Hum Genet. 1999 Nov;65(5):1342-8 [10521299.001]
  • (PMID = 18087273.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  • [Other-IDs] NLM/ PMC2361463
  •  go-up   go-down


87. Maess MB, Sendelbach S, Lorkowski S: Selection of reliable reference genes during THP-1 monocyte differentiation into macrophages. BMC Mol Biol; 2010;11:90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Reliable reference genes are a vital prerequisite for any functional study employing quantitative real-time RT-PCR (RT-qPCR) for analyzing gene expression.
  • RESULTS: The mRNA expression of 21 preselected potential reference genes was measured by RT-qPCR at several time-points over six days of PMA-induced THP-1 monocyte-to-macrophage differentiation.
  • CONCLUSION: Consequently, it is recommended to normalize any real-time PCR-based expression data obtained during THP-1 monocyte differentiation using ACTB and RPL37A.

  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Chem. 2009 Apr;55(4):611-22 [19246619.001]
  • [Cites] BMC Cancer. 2009;9:49 [19200351.001]
  • [Cites] BMC Mol Biol. 2009;10:66 [19573231.001]
  • [Cites] BMC Mol Biol. 2009;10:71 [19619301.001]
  • [Cites] Biol Cell. 2009 Dec;101(12):709-21 [19743965.001]
  • [Cites] J Biol Chem. 2009 Oct 30;284(44):30288-97 [19740737.001]
  • [Cites] Mech Ageing Dev. 2010 Feb;131(2):89-95 [20038437.001]
  • [Cites] BMC Immunol. 2010;11:21 [20441576.001]
  • [Cites] Biochem Biophys Res Commun. 2010 Sep 3;399(4):531-6 [20678479.001]
  • [Cites] J Biotechnol. 1999 Oct 8;75(2-3):291-5 [10617337.001]
  • [Cites] J Mol Endocrinol. 2000 Oct;25(2):169-93 [11013345.001]
  • [Cites] Physiol Genomics. 2000 Apr 27;2(3):143-7 [11015593.001]
  • [Cites] Biochem Biophys Res Commun. 2001 May 18;283(4):821-30 [11350058.001]
  • [Cites] J Lipid Res. 2002 Jan;43(1):26-35 [11792719.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] Curr Opin Lipidol. 2003 Oct;14(5):459-68 [14501584.001]
  • [Cites] Biotechnol Lett. 2004 Mar;26(6):509-15 [15127793.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5245-50 [15289330.001]
  • [Cites] Cancer Res. 1982 Apr;42(4):1530-6 [6949641.001]
  • [Cites] J Anat. 1987 Apr;151:27-35 [3654357.001]
  • [Cites] Experientia. 1991 Jan 15;47(1):22-31 [1999239.001]
  • [Cites] J Anat. 1993 Aug;183 ( Pt 1):97-101 [8270480.001]
  • [Cites] Am J Pathol. 1999 Feb;154(2):405-15 [10027399.001]
  • [Cites] Gene. 2005 May 23;351:119-30 [15922870.001]
  • [Cites] Methods Mol Biol. 2006;341:205-15 [16799201.001]
  • [Cites] J Leukoc Biol. 2006 Nov;80(5):1018-30 [16946020.001]
  • [Cites] J Immunol. 2006 Nov 15;177(10):7303-11 [17082649.001]
  • [Cites] Cardiovasc Res. 2007 Mar 1;73(4):833-40 [17261275.001]
  • [Cites] Biochim Biophys Acta. 2007 Jul-Aug;1769(7-8):514-24 [17628721.001]
  • [Cites] Gastroenterology. 2008 Feb;134(2):556-67 [18242221.001]
  • [Cites] Immunol Lett. 2008 Apr 15;117(1):70-80 [18276018.001]
  • [Cites] J Immunol. 2008 Apr 15;180(8):5707-19 [18390756.001]
  • [Cites] BMC Genomics. 2008;9:302 [18578872.001]
  • [Cites] J Clin Invest. 2008 Nov;118(11):3522-30 [18982158.001]
  • [Cites] J Immunol Methods. 2009 May 31;344(2):109-15 [19345690.001]
  • (PMID = 21122122.001).
  • [ISSN] 1471-2199
  • [Journal-full-title] BMC molecular biology
  • [ISO-abbreviation] BMC Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 56937-68-9 / phorbolol myristate acetate; NI40JAQ945 / Tetradecanoylphorbol Acetate
  • [Other-IDs] NLM/ PMC3002353
  •  go-up   go-down


88. Ahunbay EE, Peng C, Godley A, Schultz C, Li XA: An on-line replanning method for head and neck adaptive radiotherapy. Med Phys; 2009 Oct;36(10):4776-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Daily setup for head and neck (HN) radiotherapy (RT) can vary randomly due to neck rotation and anatomy change.
  • These differences cannot be totally corrected by the current practice of image guided RT with translational repositioning.
  • The authors present a novel rapid correction scheme that can be used on-line to correct both interfractional setup variation and anatomy change for HN RT.
  • The dose distribution for each new aperture was generated using a planning system with a fast dose engine and hardware and was input into a newly developed SWO package using fast sequential quadratic programming.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19928108.001).
  • [ISSN] 0094-2405
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Hu CY, Ding WH, Han XN, Chu SY, Hao YJ, Bu DF: [In vivo interleukin-10 gene transfer down-regulates myocardial matrix metalloproteinase and myocardial collagen expressions in rats with acute myocardial infarction]. Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Mar;36(3):243-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Five days later, the expressions of MMP-2 and MMP-9 were measured by RT-PCR, Western blot and zymography.
  • The expression of TIMP-1 was measured by RT-PCR and Western blot.
  • Collagen type I and type III were assessed by RT-PCR and immunohistochemical stain.

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Heart Attack.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19099983.001).
  • [ISSN] 0253-3758
  • [Journal-full-title] Zhonghua xin xue guan bing za zhi
  • [ISO-abbreviation] Zhonghua Xin Xue Guan Bing Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Tissue Inhibitor of Metalloproteinase-1; 130068-27-8 / Interleukin-10; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


90. Li SK, Lin CH, Chen YT, Lee LH, Liu HJ: Development of a reliable assay protocol for identification of diseases (RAPID)-bioactive amplification with probing for detection of avian reovirus. J Virol Methods; 2008 Apr;149(1):35-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of a reliable assay protocol for identification of diseases (RAPID)-bioactive amplification with probing for detection of avian reovirus.
  • This study was therefore aimed at developing a reliable assay protocol for identification of diseases (RAPID)-bioactive amplification with probing (BAP) assay for detection of ARV.
  • Two reverse transcription (RT)-PCR primer pairs, six nested PCR primer pairs, and one magnetic probe were tested to find the most specific ones for ARV detection.
  • The optimal conditions for RT-PCR, nested PCR, and hybridization of magnetic probe were established.
  • The optimal annealing temperatures for RT-PCR and nested PCR were 62.1 and 54.8 degrees C, respectively.
  • In addition, different serotypes and genotypes of ARV were tested by RAPID-BAP assay to estimate the practicability of the kit in clinical samples.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18313146.001).
  • [ISSN] 0166-0934
  • [Journal-full-title] Journal of virological methods
  • [ISO-abbreviation] J. Virol. Methods
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


91. Yashiro T, Koyama-Saegusa K, Imai T, Fujisawa T, Miyamoto T: Inhibition of potential lethal damage repair and related gene expression after carbon-ion beam irradiation to human lung cancer grown in nude mice. J Radiat Res; 2007 Sep;48(5):377-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using cultured and nude mouse tumor cells (IA) derived from a human lung cancer, we previously demonstrated their radiosensitivity by focusing attention on the dynamics of tumor clonogens and the early and rapid survival recovery (potential lethal damage repair: PLD repair) occurring after X-ray irradiation.
  • At first, colony assay method was performed after irradiation of 12 Gy of X-ray or 5 Gy of carbon-ion beam to compare the time dependent cell survival of the IA cells after each irradiation pass.
  • Second, to search the genes causing PLD repair after irradiation of X-ray or carbon-ion beam, we evaluated gene expressions by using semi-quantitative RT-PCR with the selected 34 genes reportedly related to DNA repair.
  • The intervals from the irradiation were 0, 6, 12 and 24 hr for colony assay method, and 0, 3, 18 hr for RT-PCR method.
  • The results of RT-PCR were as follows.
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Survival / radiation effects. Dose-Response Relationship, Radiation. Humans. Mice. Mice, Nude. Radiation Dosage


92. Kim WK, Meliton V, Amantea CM, Hahn TJ, Parhami F: 20(S)-hydroxycholesterol inhibits PPARgamma expression and adipogenic differentiation of bone marrow stromal cells through a hedgehog-dependent mechanism. J Bone Miner Res; 2007 Nov;22(11):1711-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PPARgamma mRNA expression assessed by RT-qPCR was significantly induced by Tro after 48 (5-fold) and 96 h (130-fold), and this induction was completely inhibited by 20S.

  • Hazardous Substances Data Bank. CYCLOPAMINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638575.001).
  • [ISSN] 0884-0431
  • [Journal-full-title] Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • [ISO-abbreviation] J. Bone Miner. Res.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / R01AR050426
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCAAT-Enhancer-Binding Protein-alpha; 0 / Hedgehog Proteins; 0 / Hydroxycholesterols; 0 / PPAR gamma; 0 / Retinoid X Receptors; 0 / Veratrum Alkaloids; 516-72-3 / 20-hydroxycholesterol; ZH658AJ192 / cyclopamine
  •  go-up   go-down


93. Pontifex MB, Hillman CH, Fernhall B, Thompson KM, Valentini TA: The effect of acute aerobic and resistance exercise on working memory. Med Sci Sports Exerc; 2009 Apr;41(4):927-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of acute aerobic and resistance exercise on working memory.
  • PURPOSE: The goal of this investigation was to assess the influence of acute bouts of aerobic versus resistance exercise on the executive control of working memory.
  • METHODS: Twenty-one young adult participants completed a cardiorespiratory fitness test and maximal strength tests.
  • On subsequent days, task performance measures of reaction time (RT) and accuracy were collected while participants completed a modified Sternberg working memory task before the start of, immediately after, and 30 min after an intervention consisting of 30 min of either resistance or aerobic exercise and a seated rest control.
  • RESULTS: Findings indicated shorter RT immediately and 30 min after acute aerobic exercise relative to the preexercise baseline with no such effects observed after resistance exercise or seated rest.
  • Further, in the aerobic condition, a larger reduction in RT from the baseline occurred during task conditions requiring increased working memory capacity.
  • Again, no effect was observed in the resistance exercise or the seated rest conditions.
  • [MeSH-minor] Female. Humans. Illinois. Physical Fitness. Reaction Time. Young Adult

  • MedlinePlus Health Information. consumer health - Exercise and Physical Fitness.
  • MedlinePlus Health Information. consumer health - Memory.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19276839.001).
  • [ISSN] 1530-0315
  • [Journal-full-title] Medicine and science in sports and exercise
  • [ISO-abbreviation] Med Sci Sports Exerc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Martin JM, Gorayski P, Zwahlen D, Fay M, Keller J, Millar J: Is radiotherapy a good adjuvant strategy for men with a history of cryptorchism and stage I seminoma? Int J Radiat Oncol Biol Phys; 2010 Jan 1;76(1):65-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • If so, the nodal echelons for metastases will not be reliable, and adjuvant radiotherapy (RT) would not be an ideal strategy.
  • The primary endpoint was the 5-year relapse-free rate.
  • RESULTS: A total of 23 men were identified, most (n = 13) had had a tumor in a scrotal location after orchiopexy.
  • After orchiectomy, 5 men were managed with surveillance, and 18 underwent RT to a median dose of 25 Gy (range, 20-30 Gy).
  • One did so 4 months into a surveillance program in the para-aortic and ipsilateral pelvic LNs, sites that would have been treated had he undergone RT.
  • The other patient developed a relapse in the contralateral testis 46 months after having undergone RT.
  • It is likely that the latter patient had a metachronous primary rather than a relapse; hence, the 5-year relapse-free rate was 80% for surveillance and 100% for RT.
  • RT, surveillance, and adjuvant carboplatin chemotherapy are treatment options for these patients.
  • [MeSH-minor] Adult. Databases, Factual. Disease-Free Survival. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Orchiopexy / adverse effects. Queensland. Radiotherapy, Adjuvant. Salvage Therapy. Tumor Burden. Victoria

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19362785.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


95. Solberg TD, Nearman J, Mullins J, Li S, Baranowska-Kortylewicz J: Correlation between tumor growth delay and expression of cancer and host VEGF, VEGFR2, and osteopontin in response to radiotherapy. Int J Radiat Oncol Biol Phys; 2008 Nov 1;72(3):918-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between tumor growth delay and expression of cancer and host VEGF, VEGFR2, and osteopontin in response to radiotherapy.
  • PURPOSE: To determine the late effects of radiotherapy (RT) on vascular endothelial growth factor (VEGF), VEGF receptor-2 (VEGFR2), and osteopontin (OPN) expression in cancer and stromal cells.
  • METHODS AND MATERIALS: LS174T xenografted athymic mice were used as a tumor model.
  • RESULTS: Tumor growth arrest was similar in all treatment groups, with the exception of a better response of small-size tumors in the 5 x 7-Gy group.
  • The host VEGF and OPN levels were directly proportional to the tumor doubling time and were independent of the fractionation scheme.
  • The host and cancer cell VEGFR2 levels in tumor were also directly related to the tumor response to RT.
  • CONCLUSION: Upregulated VEGFR2 in cancer cells suggest paracrine signaling in the VEGFR2 pathway of cancer cells as the factor contributing to RT failure.
  • The transient activation of the host VEGF/VEGFR2 pathway in tumor supports the model of angiogenic regeneration and suggests that radiation-induced upregulation of VEGF, VEGFR2, and downstream proteins might contribute to RT failure by escalating the rate of vascular repair.
  • Coexpression of host OPN and VEGF, two factors closely associated with angiogenesis, indicate that OPN can serve as a surrogate marker of tumor recovery after RT.
  • Taken together, these results strongly support the notion that to achieve optimal therapeutic outcomes, the scheduling of RT and antiangiogenic therapies will require patient-specific post-treatment monitoring of the VEGF/VEGFR2 pathway and that tumor-associated OPN can serve as an indicator of tumor regrowth.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2000 Apr;36(6):748-53 [10762747.001]
  • [Cites] Lancet Oncol. 2005 Oct;6(10):733-4 [16198974.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):39-44 [11196192.001]
  • [Cites] J Biol Chem. 2001 Feb 2;276(5):3222-30 [11058584.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10857-62 [11553814.001]
  • [Cites] Laryngoscope. 2001 Oct;111(10):1834-41 [11801954.001]
  • [Cites] Cancer J. 2002 Jan-Feb;8(1):47-54 [11895203.001]
  • [Cites] Anticancer Res. 2001 Nov-Dec;21(6B):4301-9 [11908684.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):219-27 [12086857.001]
  • [Cites] Br J Cancer. 2002 Sep 23;87(7):772-8 [12232762.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2798-805 [12231519.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] J Am Coll Surg. 2003 Sep;197(3):408-18 [12946796.001]
  • [Cites] Nat Med. 2004 Feb;10(2):145-7 [14745444.001]
  • [Cites] Int J Cancer. 1994 Nov 15;59(4):520-9 [7525492.001]
  • [Cites] Acta Neurochir Suppl. 1994;62:28-32 [7717131.001]
  • [Cites] Cancer Res. 1995 Sep 15;55(18):3964-8 [7664263.001]
  • [Cites] Nat Med. 1995 Jan;1(1):27-31 [7584949.001]
  • [Cites] Am J Pathol. 1996 Jul;149(1):293-305 [8686754.001]
  • [Cites] Endocr Rev. 1997 Feb;18(1):4-25 [9034784.001]
  • [Cites] J Natl Cancer Inst. 1997 Jun 18;89(12):881-6 [9196255.001]
  • [Cites] Cancer Metastasis Rev. 1998 Jun;17(2):155-61 [9770111.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):836-41 [16751064.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1391-8 [16965868.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11520-39 [17178843.001]
  • [Cites] Nat Clin Pract Oncol. 2007 May;4(5):316-21 [17464339.001]
  • [Cites] Oncologist. 2007 Apr;12(4):465-77 [17470689.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):472-8 [17498568.001]
  • [Cites] Oncol Rep. 2007 Sep;18(3):709-14 [17671724.001]
  • [Cites] Lancet Oncol. 2008 Apr;9(4):342-51 [18343725.001]
  • [Cites] Exp Neurol. 1998 Dec;154(2):691-5 [9878204.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3374-8 [10416597.001]
  • [Cites] Urology. 1999 Sep;54(3):567-72 [10475375.001]
  • [Cites] Am J Respir Crit Care Med. 1999 Oct;160(4):1269-73 [10508818.001]
  • [Cites] Cancer Cell. 2004 Dec;6(6):553-63 [15607960.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8587-93 [15623642.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):835-42 [15701874.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):908-14 [15708274.001]
  • [Cites] J Exp Med. 2005 Sep 19;202(6):739-50 [16157686.001]
  • [Cites] J Neurooncol. 2005 Sep;74(2):99-103 [16193379.001]
  • [Cites] Oncologist. 2000;5 Suppl 1:3-10 [10804084.001]
  • (PMID = 19014781.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA095267-03; United States / NCI NIH HHS / CA / R01 CA095267-03; United States / NCI NIH HHS / CA / R01 CA095267; United States / NCI NIH HHS / CA / CA095267-02; United States / NCI NIH HHS / CA / R01CA95267; United States / NCI NIH HHS / CA / R01 CA095267-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A; 106441-73-0 / Osteopontin; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  • [Other-IDs] NLM/ NIHMS74477; NLM/ PMC2585106
  •  go-up   go-down


96. Malo MS, Mozumder M, Zhang XB, Biswas S, Chen A, Bai LC, Merchant JL, Hodin RA: Intestinal alkaline phosphatase gene expression is activated by ZBP-89. Am J Physiol Gastrointest Liver Physiol; 2006 Apr;290(4):G737-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RT-PCR, quantitative real-time RT-PCR, Western blot analyses, and reporter assays were used to determine the regulation of IAP by ZBP-89 in HT-29 and Caco-2 colon cancer cells.
  • The results of RT-PCR, quantitative real-time PCR, and Western blot analyses showed that ZBP-89 was expressed at low levels in Caco-2 and HT-29 cells, whereas IAP was minimally expressed and absent in these cells, respectively.
  • These findings are consistent with the role that this transcription factor is thought to play as a tumor suppressor and suggests its possible function in the physiology of fat absorption.

  • COS Scholar Universe. author profiles.
  • GeneTex Inc. NCBI Redirect Page | Genetex Inc. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16384873.001).
  • [ISSN] 0193-1857
  • [Journal-full-title] American journal of physiology. Gastrointestinal and liver physiology
  • [ISO-abbreviation] Am. J. Physiol. Gastrointest. Liver Physiol.
  • [Language] eng
  • [Grant] United States / PHS HHS / / R01-55732; United States / NIDDK NIH HHS / DK / R01-DK-47186; United States / NIDDK NIH HHS / DK / R01-DK-55732
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Transcription Factors; 0 / ZNF148 protein, human; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


97. Hanamura K, Mizui T, Kakizaki T, Roppongi RT, Yamazaki H, Yanagawa Y, Shirao T: Low accumulation of drebrin at glutamatergic postsynaptic sites on GABAergic neurons. Neuroscience; 2010 Sep 15;169(4):1489-500
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low accumulation of drebrin at glutamatergic postsynaptic sites on GABAergic neurons.
  • Glutamatergic synapses form onto both glutamatergic and GABAergic neurons.
  • These two types of glutamatergic synapses differ in their electrical responses to high-frequency stimulation and postsynaptic density protein composition.
  • However, it is not known whether they differ in the actin cytoskeleton composition.
  • In the present study, we used hippocampal neuronal cultures prepared from glutamate decarboxylase 67 (GAD67)-GFP knock-in mice and analyzed the differences in the actin cytoskeleton at glutamatergic synapses contacting GABAergic and glutamatergic neurons.
  • Drebrin-binding actin filaments enriched in dendritic spines are known to play a pivotal role in spine formation.
  • Immunocytochemical analyses demonstrated that drebrin accumulated at glutamatergic synapses on GABAergic neurons as well as at those on glutamatergic neurons.
  • However, the density of drebrin clusters along dendrites in GABAergic neurons was significantly lower than those of glutamatergic neurons.
  • Furthermore, the level of drebrin accumulating at glutamatergic synapses was lower on GABAergic neurons than on glutamatergic neurons.
  • In neurons overexpressing drebrin, drebrin cluster density and accumulation levels in GABAergic and glutamatergic neurons were similar, suggesting that the low drebrin levels in the glutamatergic postsynaptic sites on GABAergic neurons may be because GABAergic neurons express low levels of drebrin.
  • On the other hand, pharmacological analysis demonstrated that the postsynaptic localization of drebrin depended on actin cytoskeleton organization in both GABAergic and glutamatergic neurons.
  • Together these results indicated that, although GABAergic and glutamatergic neurons share common regulatory systems affecting drebrin localization, the density of drebrin-positive glutamatergic synapses formed on GABAergic neurons is lower than those on glutamatergic neurons.
  • This is probably due to the low expression of drebrin in GABAergic neurons.
  • [MeSH-major] Dendritic Spines / metabolism. Glutamic Acid / metabolism. Hippocampus / metabolism. Neuropeptides / metabolism. Synapses / metabolism. gamma-Aminobutyric Acid / metabolism
  • [MeSH-minor] Animals. Animals, Newborn. Cells, Cultured. Gene Knock-In Techniques. Mice. Mice, Inbred C57BL. Mice, Transgenic. Rats. Rats, Wistar

  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 IBRO. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20600648.001).
  • [ISSN] 1873-7544
  • [Journal-full-title] Neuroscience
  • [ISO-abbreviation] Neuroscience
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neuropeptides; 0 / drebrins; 3KX376GY7L / Glutamic Acid; 56-12-2 / gamma-Aminobutyric Acid
  •  go-up   go-down


98. Pancioli AM, Broderick J, Brott T, Tomsick T, Khoury J, Bean J, del Zoppo G, Kleindorfer D, Woo D, Khatri P, Castaldo J, Frey J, Gebel J Jr, Kasner S, Kidwell C, Kwiatkowski T, Libman R, Mackenzie R, Scott P, Starkman S, Thurman RJ, CLEAR Trial Investigators: The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial. Stroke; 2008 Dec;39(12):3268-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial.
  • Treatment of myocardial infarction with a combination of a reduced-dose fibrinolytic agent and a glycoprotein (GP) IIb/IIIa receptor antagonist has been shown to improve the rate of recanalization versus fibrinolysis alone.
  • The combined approach to lysis utilizing eptifibatide and recombinant tissue-type plasminogen activator (rt-PA) (CLEAR) stroke trial assessed the safety of treating acute ischemic stroke patients within 3 hours of symptom onset with this combination.
  • Patients were randomized 3:1 to either low-dose rt-PA (tier 1=0.3 mg/kg, tier 2=0.45 mg/kg) plus eptifibatide (75 microg/kg bolus followed by 0.75 microg/kg per min infusion for 2 hours) or standard-dose rt-PA (0.9 mg/kg).
  • The primary safety end point was the incidence of symptomatic intracerebral hemorrhage within 36 hours.
  • The combination group of the 2 dose tiers (n=69) had a median age of 71 years and a median baseline National Institutes of Health Stroke Scale (NIHSS) score of 14, and the standard-dose rt-PA group (n=25) had a median age of 61 years and a median baseline NIHSS score of 10 (P=0.01 for NIHSS score).
  • There was 1 (1.4%; 95% CI, 0% to 4.3%) symptomatic intracranial hemorrhage in the combination group and 2 (8.0%; 95% CI, 0% to 19.2%) in the rt-PA-only arm (P=0.17).
  • There was a trend toward increased clinical efficacy of standard-dose rt-PA compared with the combination treatment group.
  • CONCLUSIONS: The safety of the combination of reduced-dose rt-PA plus eptifibatide justifies further dose-ranging trials in acute ischemic stroke.

  • Genetic Alliance. consumer health - Ischemic stroke.
  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stroke. 2000 Jun;31(6):1402-09; discussion 1409-10 [10835463.001]
  • [Cites] JAMA. 2001 May 16;285(19):2468-73 [11368699.001]
  • [Cites] Lancet. 2001 Jun 16;357(9272):1905-14 [11425410.001]
  • [Cites] Brain Res. 2001 Sep 7;912(2):181-94 [11532435.001]
  • [Cites] Neurology. 2002 Sep 24;59(6):862-7 [12297567.001]
  • [Cites] Stroke. 2004 Oct;35(10):2418-24 [15345796.001]
  • [Cites] Stroke. 1986 Nov-Dec;17(6):1254-65 [3810730.001]
  • [Cites] AJNR Am J Neuroradiol. 1993 Jan-Feb;14(1):3-13 [8427107.001]
  • [Cites] Am J Pathol. 1994 Jan;144(1):188-99 [8291608.001]
  • [Cites] Circulation. 1995 Apr 15;91(8):2151-7 [7697843.001]
  • [Cites] N Engl J Med. 1995 Dec 14;333(24):1581-7 [7477192.001]
  • [Cites] Lancet. 1997 May 17;349(9063):1422-8 [9164315.001]
  • [Cites] N Engl J Med. 1998 Aug 13;339(7):436-43 [9705684.001]
  • [Cites] J Clin Invest. 1998 Oct 1;102(7):1301-10 [9769322.001]
  • [Cites] Circulation. 1999 May 11;99(18):2371-7 [10318656.001]
  • [Cites] CNS Drugs. 2004;18(14):981-8 [15584768.001]
  • [Cites] J Cereb Blood Flow Metab. 2005 Jan;25(1):87-97 [15678115.001]
  • [Cites] Am J Cardiol. 2005 Mar 1;95(5):611-4 [15721101.001]
  • [Cites] Stroke. 2007 Feb;38(2):431-40 [17234988.001]
  • [Cites] Stroke. 2008 Jan;39(1):87-99 [18032739.001]
  • (PMID = 18772447.001).
  • [ISSN] 1524-4628
  • [Journal-full-title] Stroke; a journal of cerebral circulation
  • [ISO-abbreviation] Stroke
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / K23 NS054084-04; United States / NINDS NIH HHS / NS / R37 NS038710-08; United States / NINDS NIH HHS / NS / R37 NS038710; United States / NINDS NIH HHS / NS / T32 NS047996; United States / NINDS NIH HHS / NS / R01 NS053716; United States / NINDS NIH HHS / NS / 1 P50 NS44283-01; United States / NINDS NIH HHS / NS / P50 NS044283; United States / NINDS NIH HHS / NS / NS038710-08; United States / NINDS NIH HHS / NS / NS053716-04; United States / NINDS NIH HHS / NS / NS044283-010001; United States / NINDS NIH HHS / NS / P50 NS044283-010001; United States / NINDS NIH HHS / NS / R01 NS053716-04; United States / NINDS NIH HHS / NS / K23 NS054084
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fibrinolytic Agents; 0 / Peptides; 0 / Platelet Aggregation Inhibitors; 0 / Recombinant Proteins; 0 / eptifibatide; EC 3.4.21.68 / Tissue Plasminogen Activator
  • [Other-IDs] NLM/ NIHMS78844; NLM/ PMC2588546
  • [Investigator] Broderick J; Kwiatkowski T; Libman R; Castaldo J; Mackenzie R; Scott P; Frey J; Kasner SE; Thurman RJ; Starkman S; Gebel J Jr; Janis S; Brott T; del Zoppo G; Tomsick T; Kidwell C; Bean J; Khoury J; Levine S; Brass L; Tietjens G; Welch KM; Clarke WR; Schmit P; Ewing I; Spilker J; Zeigler J; Carrozzella J; Gonzaga-Camfield R; Manlulu M; Schaefer M; Cerrone M; Fox C; Jenny D; Knapp K; Mathiesen C; Rodgers J; Frederiksen S; Maddox K; Murrell T; Sandretto A; Kurzer S; Sellers M; Luciano J; Brown D; Guzy J; Adkisson P; Constant R; Woo D; Kleindorfer D; Khatri P; Adeoye O; Flaherty M; Jauch E; Kanter D; Kissela B; Nichols C; Schneider A; Stettler B; Schoenberg L; Barbour P; Clauser G; Rae-Grant A; Isayev Y; Li Y; Mackin G; Margraf J; Spikol L; Varrato J; Barsan W; Brown D; Hickenbottom S; Majersik J; Meurer W; Morgenstern L; Silbergleit R; Smith R; Smith T; Wang M; Zahuranec D; Cucchiara B; Messe S; Pacelli J; Sansing L; Shah Q; Gaines K; Kirshner H; O'Duffy A; Jarquin-Valdivia A; Ali L; Amos E; Buck B; Buxton W; Fredieu A; Gold M; Jordan S; Kim D; Liebeskind D; Miller C; O'Connor E; Oh A; Ovbiagele B; Porter V; Rajajee V; Restrepo L; Sanossian N; Selco S; Shah S; Shimizu R; Suzuki S; Towfighi A; Vespa P; Woo A; Sauerbeck L; Brock J; Combs B
  •  go-up   go-down


99. Gouin S, Robidas I, Gravel J, Guimont C, Chalut D, Amre D: Prospective evaluation of two clinical scores for acute asthma in children 18 months to 7 years of age. Acad Emerg Med; 2010 Jun;17(6):598-603
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients 18 months to 7 years of age who presented for an asthma exacerbation were eligible.
  • The primary outcome was a length of stay (LOS) of >6 hours in the ED or admission to the hospital.
  • Clinical findings and components of the PRAM and the PASS were assessed by a respiratory therapist (RT) at the start of the ED visit and after 90 minutes of treatment.

  • Genetic Alliance. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 by the Society for Academic Emergency Medicine.
  • (PMID = 20624139.001).
  • [ISSN] 1553-2712
  • [Journal-full-title] Academic emergency medicine : official journal of the Society for Academic Emergency Medicine
  • [ISO-abbreviation] Acad Emerg Med
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


100. Borkamo ED, Dahl O, Bruland O, Fluge Ø: Kinetics study on markers of the immune system by gene expression profiling of an in vivo heated tumor. Int J Hyperthermia; 2009 Feb;25(1):41-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kinetics study on markers of the immune system by gene expression profiling of an in vivo heated tumor.
  • PURPOSE: To analyze effects of hyperthermia on immune cells within tumors.
  • MATERIALS AND METHODS: Subcutaneously implanted rat gliomas were treated with water-bath hyperthermia for one hour at day zero (HT) (intratumoral temperature of 43 degrees C), low-dose metronomic cyclophosphamide (CTX) 35 mg/kg three times a week for two weeks, both HT and CTX (CTX-HT(0)), or saline.
  • Tumors harvested at day 1, 7, 14 and 21 were analyzed for changes in gene expression by microarrays, focusing on genes expressed in immune cells.
  • Microarray analyses and real-time RT-PCR were previously performed on tumors harvested day zero at 0, 45, 90 and 180 minutes after end of treatment.
  • Gene expression kinetics of selected genes were analyzed in all tumors by quantitative real-time RT-PCR (qPCR) to validate the results of the microarrays.
  • RESULTS: Previous microarray analyses have indicated a suppression of gene expression in immune cells within tumors by hyperthermia the first three hours after treatment. qPCR analyses of CD14, CD36, Klrd1 (CD94), Tlr2 and Lrp1 confirmed these results.
  • CONCLUSION: The suppression in gene expression of a range of immune cells within tumors treated with hyperthermia at 43 degrees C is a transient phenomenon.
  • [MeSH-major] Biomarkers / metabolism. Hyperthermia, Induced. Immune System / physiology. Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Immune System and Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19219699.001).
  • [ISSN] 1464-5157
  • [Journal-full-title] International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  • [ISO-abbreviation] Int J Hyperthermia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down






Advertisement